<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        14-960-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SPRYCEL 20MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DASATINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6157.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca Pharmaceuticals LP" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca Pharmaceuticals LP
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BRISTOL-MYERS SQUIBB
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPRYCEL is a prescription medicine used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults with Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including imatinib.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; children 1 year of age and older with Ph+ CML in chronic phase.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; children 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.</p><p>It is not known if SPRYCEL is safe and effective in children under 1 year of age.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take SPRYCEL</strong></p><p>if you are allergic to dasatinib or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>If you could </strong><strong>be allergic, ask your doctor for advice.</strong></p><p><strong>Warnings and precautions </strong></p><p><strong>Before taking SPRYCEL, tell your healthcare provider about all of your medical conditions, including if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have problems with your immune system</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have heart problems, including a condition called congenital long QT syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have low potassium or low magnesium levels in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are lactose (milk sugar) intolerant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had or might now have a hepatitis B infection. This is because SPRYCEL could cause hepatitis B to become active again, which can be fatal in some cases. Patients will be carefully checked by their doctor for signs of this infection before treatment is started.</p><p><strong>Children</strong></p><p>It is not known if SPRYCEL is safe and effective in children under 1 year of age.</p><p><strong>Other medicines and SPRYCEL</strong></p><p><strong>Tell your healthcare provider about all the medicines you take,</strong> including prescription and over-the-counter medicines, vitamins, antacids, and herbal supplements. <strong>If you take an antacid medicine, take it 2 hours before or 2 hours after your dose of SPRYCEL.</strong></p><p>&nbsp;</p><p>SPRYCEL is mainly handled by the liver. Certain medicines may interfere with the effect of SPRYCEL when taken together.</p><p>&nbsp;</p><p><strong>These medicines are not to be used with SPRYCEL:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole, itraconazole &ndash; these are <strong>antifungal medicines</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythromycin, clarithromycin, telithromycin &ndash; <strong>these are antibiotics</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir &ndash; this is an <strong>antiviral medicine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, carbamazepine, phenobarbital &ndash; these are treatments for <strong>epilepsy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin &ndash; this is a treatment for <strong>tuberculosis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; famotidine, omeprazole &ndash; these are medicines that <strong>block stomach acids</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort &ndash; a herbal preparation obtained without a prescription, used to treat <strong>depression </strong>and other conditions (also known as <em>Hypericum perforatum)</em></p><p>&nbsp;</p><p><strong>Do not take</strong> medicines that neutralize stomach acids (<strong>antacids</strong> such as aluminum hydroxide or magnesium hydroxide) in the <strong>2 hours before or 2 hours after taking SPRYCEL.</strong></p><p>&nbsp;</p><p><strong>Tell your doctor</strong> if you are taking <strong>medicines to thin the blood</strong> or prevent clots.</p><p><strong>SPRYCEL with food and drink</strong></p><p>Take SPRYCEL with or without food.</p><p>You should not drink grapefruit juice during treatment with SPRYCEL.</p><p><strong>Pregnancy and breastfeeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. SPRYCEL can harm your unborn baby.</p><p><strong>Females who can become pregnant:</strong></p><p>o&nbsp;&nbsp; You should not become pregnant during treatment with SPRYCEL.</p><p>o&nbsp;&nbsp; You should use effective birth control (contraception) during treatment and for 30 days after your last dose of SPRYCEL.</p><p>o&nbsp;&nbsp; Talk to your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with SPRYCEL.</p><p><strong>Males with female partners who can become pregnant:</strong></p><p>o&nbsp;&nbsp; You should use effective birth control (contraception) during treatment and for 30 days after your last dose of SPRYCEL.</p><p>o&nbsp;&nbsp; Your female partner should call her healthcare provider if she becomes pregnant or thinks she is pregnant during your treatment with SPRYCEL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if SPRYCEL passes into your breast milk. You should not breastfeed during treatment and for 2 weeks after your last dose of SPRYCEL.</p><p><strong>Women who are pregnant should not handle crushed or broken SPRYCEL tablets.</strong></p><p><strong>Driving</strong><strong> </strong><strong>and using machines</strong></p><p>No studies on the effects on the ability to drive and use machines have been performed. Patients should be advised that they may experience adverse reactions such as dizziness or blurred vision during treatment with dasatinib. Therefore, caution should be recommended when driving a car or operating machines.</p><p><strong>SPRYCEL contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPRYCEL is an antineoplastic drug. Need caution when handling SPRYCEL to minimize risk of exposure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPRYCEL treatment must be initiated and monitored under the supervision of a physician experienced in the antineoplastic agents.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; People who are not taking SPRYCEL should not be exposed to it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablets should be swallowed whole.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets should not be broken or crushed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take SPRYCEL exactly as your healthcare provider tells you to take it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your healthcare provider may change your dose of SPRYCEL or temporarily stop treatment with SPRYCEL. <strong>Do not change your dose or stop taking SPRYCEL without first talking to your healthcare provider.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take SPRYCEL 1 time a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take SPRYCEL with or without food, either in the morning or in the evening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow SPRYCEL tablets whole. Do not crush, break, cut or chew the tablets.</p><p>o&nbsp;&nbsp; If your child cannot swallow tablets whole, talk with your healthcare provider.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not drink grapefruit juice during treatment with SPRYCEL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose of SPRYCEL, take your next scheduled dose at your regular time. Do not take two doses at the same time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take too much SPRYCEL, call your healthcare provider or go to the nearest hospital emergency room right away.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, SPRYCEL can cause side effects, although not everybody gets them.</p><p><strong>SPRYCEL may cause serious side effects, including:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Low blood cell counts.</strong> Low blood cell counts are common with SPRYCEL and can be severe, including low red blood cell counts (anemia), low white blood cell counts (neutropenia), and low platelet counts (thrombocytopenia). Your healthcare provider will do blood tests to check your blood cell counts regularly during your treatment with SPRYCEL. Call your healthcare provider right away if you have a fever or any signs of an infection during treatment with SPRYCEL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bleeding problems</strong>. Bleeding problems are common with SPRYCEL. Sometimes these bleeding problems can be serious and lead to death. Call your healthcare provider right away if you have:</p><p>o&nbsp;&nbsp; unusual bleeding or bruising of your skin</p><p>o&nbsp;&nbsp; bright red or dark tar-like stools</p><p>o&nbsp;&nbsp; decreased alertness, headache, or change in speech</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Your body may hold too much fluid (fluid retention).</strong> Fluid retention is common with SPRYCEL and can sometimes be severe. In severe cases, fluid may build up in the lining of your lungs, the sac around your heart, or your stomach cavity. Call your healthcare provider right away if you get any of these symptoms during treatment with SPRYCEL:</p><p>o&nbsp;&nbsp; swelling all over your body</p><p>o&nbsp;&nbsp; weight gain</p><p>o&nbsp;&nbsp; shortness of breath, especially if this happens with low levels of physical activity or at rest</p><p>o&nbsp;&nbsp; dry cough</p><p>o&nbsp;&nbsp; chest pain when taking a deep breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart and blood vessel (cardiovascular)</strong><strong> problems</strong>. SPRYCEL may cause heart problems, including an abnormal heart rate, a heart attack, or small strokes that last only a few minutes or a few hours, called transient ischemic attacks (TIAs). TIAs are often a warning sign that you are at risk for a more serious stroke. Your healthcare provider will monitor the potassium and magnesium levels in your blood and your heart function.</p><p>Get medical help right away if you develop any of the following symptoms during treatment with SPRYCEL:</p><p>o&nbsp;&nbsp; chest pain</p><p>o&nbsp;&nbsp; shortness of breath</p><p>o&nbsp;&nbsp; feeling like your heart is beating too fast or you feel abnormal heart beats</p><p>o&nbsp;&nbsp; vision changes that may last for a short time</p><p>o&nbsp;&nbsp; slurred speech</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pulmonary Arterial Hypertension (PAH).</strong> SPRYCEL may cause high blood pressure in the vessels of your lungs. PAH may happen at any time during your treatment with SPRYCEL. Your healthcare provider should check your heart and lungs before and during treatment with SPRYCEL. Call your healthcare provider right away if you have shortness of breath, tiredness, or swelling all over your body (fluid retention).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Severe skin reactions.</strong> SPRYCEL may cause skin reactions that can sometimes be severe. Get medical help right away if you get a skin reaction with fever, sore mouth or throat, or blistering or peeling of your skin or in the mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tumor Lysis Syndrome (TLS).</strong> TLS is caused by a fast breakdown of cancer cells. TLS can cause you to have kidney failure and the need for dialysis treatment, and an abnormal heartbeat. Your healthcare provider may do blood tests to check you for TLS. Call your healthcare provider or get emergency medical help right away if you develop any of these symptoms during treatment with SPRYCEL:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; nausea</p><p>o&nbsp;&nbsp; vomiting</p><p>o&nbsp;&nbsp; weakness</p><p>o&nbsp;&nbsp; swelling</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; shortness of breath</p><p>o&nbsp;&nbsp; muscle cramps</p><p>o&nbsp;&nbsp; seizures</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Slowing of growth and development in children. </strong>Effects on bone growth and development in children have happened with SPRYCEL and can sometimes be severe. Your healthcare provider will monitor your child&rsquo;s bone growth and development during treatment with SPRYCEL. Get medical help right away if your child develops bone pain.</p><p>The most common side effects of SPRYCEL in adults and children receiving SPRYCEL alone include:</p><table border="0" cellspacing="0" cellpadding="0" style="width:643px"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>&nbsp;</p></td></tr></tbody></table><p>The most common side effects of SPRYCEL in children receiving SPRYCEL with chemotherapy include:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, pain and redness of the lining of your mouth, throat, stomach and bowel (mucositis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low white blood cell counts with fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach-area (abdominal) pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or tingling of your hands and feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused or disoriented</p><p>&nbsp;</p></td></tr></tbody></table><p>SPRYCEL may cause fertility problems in males and females. Talk to your healthcare provider if this is a concern for you.</p><p><strong>Very</strong><strong> common side effects (may affect more than 1 in 10 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections:</strong> (including bacterial, viral and fungal)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart and lungs:</strong> shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Digestive problems:</strong> diarrhea, feeling or being sick (nausea, vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin, hair, eye, general:</strong> skin rash, fever, swelling around the face, hands, and feet, headache, feeling tired or weak, bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pain:</strong> pain in the muscles (during or after discontinuing treatment), tummy (abdominal) pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tests may show:</strong> low blood platelet count, low white blood cells count (neutropenia), anemia, fluid around the lungs</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections:</strong> pneumonia, herpes virus infection (including cytomegalovirus - CMV), upper respiratory tract infection, serious infection of the blood or tissues (including uncommon cases with fatal outcomes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart and lungs:</strong> palpitations, irregular heartbeat, congestive heart failure, weak heart muscle, high blood pressure, increased blood pressure in the lungs, cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Digestive problems:</strong> appetite disturbances, taste disturbance, bloated or distended tummy (abdomen), inflammation of the colon, constipation, heartburn, mouth ulceration, weight increase, weight decrease, gastritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin, hair, eye, general: </strong>skin tingling, itching, dry skin, acne, inflammation of the skin, persistent noise in ears, hair loss, excessive perspiration, visual disorder (including blurred vision and disturbed vision), dry eye, bruise, depression, insomnia, flushing, dizziness, contusion (bruising), anorexia, somnolence, generalized edema</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pain:</strong> pain in joints, muscular weakness, chest pain, pain around hands and feet, chills, stiffness in muscles and joints, muscle spasm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tests may show:</strong> fluid around the heart, fluid in the lungs, arrhythmia, febrile neutropenia, gastrointestinal bleeding, high uric acid levels in the blood</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart and lungs:</strong> heart attack (including fatal outcome), inflammation of the lining (fibrous sack) surrounding the heart, irregular heartbeat, chest pain due to lack of blood supply to the heart (angina), low blood pressure, narrowing of airway that may cause breathing difficulties, asthma, increased blood pressure in the arteries (blood vessels) of the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Digestive problems:</strong> inflammation of the pancreas, peptic ulcer, inflammation of the food pipe, swollen tummy (abdomen), tear in the skin of the anal canal, difficulty in swallowing, inflammation of the gallbladder, blockage of bile ducts, gastroesophageal reflux (a condition where acid and other stomach contents come back up into the throat)</p><p>&middot;&nbsp; <strong>Skin, hair, eye, general:</strong> allergic reaction including tender, red lumps on the skin (erythema nodosum), anxiety, confusion, mood swings, lower sexual drive, fainting, tremor, inflammation of the eye which causes redness or pain, a skin disease characterized by tender, red, well-defined blotches with the sudden onset of fever and raised white blood cell count (neutrophilic dermatosis), loss of hearing, sensitivity to light, visual impairment, increased eye tearing, disturbance in skin color, inflammation of fatty tissue under the skin, skin ulcer, blistering of the skin, nail disorder, hair disorder, hand-foot disorder, renal failure, urinary frequency, breast enlargement in men, menstrual disorder, general weakness and discomfort, low thyroid function, losing balance while walking, osteonecrosis (a disease of reduced blood flow to the bones, which can cause bone loss and bone death), arthritis, skin swelling anywhere in the body</p><p>&middot;&nbsp; <strong>Pain:</strong> inflammation of vein which can cause redness, tenderness and swelling, inflammation of the tendon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Brain:</strong> loss of memory</p><p>&middot;&nbsp; <strong>Tests may show:</strong> abnormal blood test results and possibly impaired kidney function caused by the waste products of the dying tumor (tumor lysis syndrome), low levels of albumin in the blood, low levels of lymphocytes (a type of white blood cell) in the blood, high level of cholesterol in the blood, swollen lymph nodes, bleeding in the brain, irregularity of the electrical activity of the heart, enlarged heart, inflammation of the liver, protein in the urine, raised creatine phosphokinase (an enzyme mainly found in the heart, brain and skeletal muscles), raised troponin (an enzyme mainly found in the heart and skeletal muscles), raised gamma-glutamyltransferase (an enzyme mainly found in the liver), milky-appearing fluid around the lungs (chylothorax)</p><p>&nbsp;</p><p><strong>Rare </strong><strong>side effects (may affect up to 1 in 1,000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart and lungs:</strong> enlargement of the right ventricle in the heart, inflammation of the heart muscle, collection of conditions resulting from blockage of blood supply to the heart muscle (acute coronary syndrome), cardiac arrest (stopping of blood flow from the heart), coronary (heart) artery disease, inflammation of the tissue covering the heart and lungs, blood clots, blood clots in the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Digestive problems:</strong> loss of vital nutrients such as protein from your digestive tract, bowel obstruction, anal fistula (an abnormal opening from the anus to the skin around the anus), impairment of kidney function, diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin, hair, eye, general:</strong> convulsion, inflammation of the optic nerve that may cause a complete or partial loss of vision, blue-purple mottling of the skin, abnormally high thyroid function, inflammation of the thyroid gland, ataxia (a condition associated with lack of muscular coordination), difficulty walking, miscarriage, inflammation of the skin blood vessels, skin fibrosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Brain:</strong> stroke, temporary episode of neurologic dysfunction caused by loss of blood flow, facial nerve paralysis, dementia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Immune system:</strong> severe allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Musculoskeletal and connective tissue:</strong> delayed fusion of the rounded ends that form joints (epiphyses); slower or delayed growth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tests may show:</strong> insufficient red blood cell production</p><p>&nbsp;</p><p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of SPRYCEL.</p><p>Call your doctor for medical advice about side effects.</p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your healthcare provider.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPRYCEL is an antineoplastic medication. To minimize risk of exposure, caution is required when handling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; People who are not taking SPRYCEL should not be exposed to it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transport and store medicine in the original container or blister.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For medication administration, use gloves and wash hands thoroughly before and after. If gloves are not worn, tip tablets from their container/blister pack directly into a disposable medicine cup.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets should not be divided, broken, or crushed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wear latex or nitrile gloves when handling tablets that have accidently been crushed or broken.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; People who are pregnant should avoid exposure to crushed or broken coated tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution should be observed in handling broken or crushed tablets. Avoid direct contact of SPRYCEL with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Family members must use gloves when handling laundry or cleaning inside or around toilets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If available, use separate bathroom from family members. Close the lid before flushing the toilet and flush twice after each use by patient, for 48 hours after receiving chemotherapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conduct double washing of linens and wash them separately from other family laundry.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep SPRYCEL and all medicines out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store SPRYCEL at room temperature between 20&deg;C to 25&deg;C. Do not store SPRYCEL above 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking SPRYCEL, or your medication has expired, do not throw away via wastewater or household waste. Ask your pharmacist how to throw away medicine you no longer use, or return it to your pharmacist, who will destroy it according to disposal of dangerous substance guidelines. These measures will help protect the environment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only keep the medicine if your doctor tells you to.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:77pt; margin-right:0in; text-align:left; text-indent:-0.5in"><!--[if !supportLists]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Active ingredient: dasatinib</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inactive ingredients in SPRYCEL Tablets: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate. The tablet coating consists of hypromellose, titanium dioxide, and polyethylene glycol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                SPRYCEL Tablets are available as follows:
•	SPRYCEL 20 mg: the film-coated tablet is white to off-white, biconvex, round with “BMS” debossed on one side and “527” on the other side.
•	SPRYCEL 50 mg: the film-coated tablet is white to off-white, biconvex, oval with “BMS” debossed on one side and “528” on the other side.
•	SPRYCEL 70 mg: the film-coated tablet is white to off-white, biconvex, round with “BMS” debossed on one side and “524” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder: </strong></p><p>Bristol-Myers Squibb Company</p><p>Princeton, New Jersey 08543 USA</p><p>&nbsp;</p><p><strong>Manufactured by:</strong></p><p>AstraZeneca Pharmaceuticals LP</p><p>4601 Highway 62 East</p><p>Mount Vernon, Indiana 47620 USA</p><p>&nbsp;</p><p>Patheon Inc</p><p>2100 Syntex Court, Mississauga</p><p>Ontario L5N 7K9</p><p>Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in Feb. 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">.&nbsp; ما هو سبرايسل وما هي دواعي استخدامه</p><p dir="RTL">سبرايسل دواء يصرف بوصفة طبية يستخدم في علاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﺒﺎﻟﻐﻮن اﻟﺬﯾﻦ ﺷﺨﺼﻮا ﻣﺆﺧﺮاً ﺑﺈﺻﺎﺑﺘﮭﻢ ﺑﺎﻟﻠﻮﻛﯿﻤﯿﺎ اﻟﻨﺨﺎﻋﯿﺔ اﻟﻤﺰﻣﻨﺔ (CML) ﻣﻊ وﺟﻮد ﻛﺮوﻣﻮﺳﻮم ﻓﯿﻼدﻟﻔﯿﺎ (+Ph) ﻓﻲ ﻣﺮﺣﻠﺔ ﻣﺰﻣﻨﺔ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغون المصابون باللوكيميا النخاعية المزمنة (CML) مع وجود كروموسوم فيلادلفيا (+Ph) الذين لم تعد العلاجات الأخرى تجدي معهم أو لا يتحملونها بما في ذلك إيماتينب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغون المصابون بلوكيميا الأرومة اللمفاوية الحادة مع وجود كروموسوم فيلادلفيا (Ph+ ALL) الذين لم تعد العلاجات الأخرى تجدي معهم أو لا يتحملونها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻷطﻔﺎل ﺑﻌﻤﺮ ﻋﺎم واﺣﺪ وأﻛﺒﺮ اﻟﻤﺼﺎﺑﻮن ﺑﺎﻟﻠﻮﻛﯿﻤﯿﺎ اﻟﻨﺨﺎﻋﯿﺔ اﻟﻤﺰﻣﻨﺔ (CML) ﻣﻊ وﺟﻮد ﻛﺮوﻣﻮﺳﻮم ﻓﯿﻼدﻟﻔﯿﺎ (+Ph)&nbsp; ﻓﻲ ﻣﺮﺣﻠﺔ ﻣﺰﻣﻨﺔ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻷطﻔﺎل ﺑﻌﻤﺮ ﻋﺎم واﺣﺪ وأﻛﺒﺮ اﻟﺬﯾﻦ ﺷﺨﺼﻮا ﻣﺆﺧﺮاً ﺑﺈﺻﺎﺑﺘﮭﻢ ﺑﻠﻮﻛﯿﻤﯿﺎ اﻷروﻣﺔ اﻟﻠﻤﻔﺎوﯾﺔ اﻟﺤﺎدة ﻣﻊ وﺟﻮد ﻛﺮوﻣﻮﺳﻮم&nbsp; ﻓﯿﻼدﻟﻔﯿﺎ (Ph+ ALL) ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ اﻟﻌﻼج اﻟﻜﯿﻤﯿﺎﺋﻲ.&nbsp;</p><p dir="RTL">لا يُعرف إذا ما كان سبرايسل آمناً وفعالاً للأطفال الذين يقل عمرهم عن عام واحد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل سبرايسل</strong></p><p dir="RTL">إذا كنت مصاباً بحساسية لمادة داساتينيب أو لأي من مكونات الدواء الأخرى (المذكورة في القسم 6).</p><p dir="RTL"><strong>إذا كان من الممكن أن تكون </strong><strong>مصاباً بحساسية، فاطلب المشورة من طبيبك.</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات </strong></p><p dir="RTL"><strong>قبل تلقي سبرايسل، أخبر مقدم الرعاية الصحية بجميع حالاتك الصحية، وذلك يشمل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمشاكل في جهازك المناعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمشاكل في القلب، بما في ذلك حالة تُعرف باسم متلازمة QT الطويلة الخلقية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني انخفاضاً في مستويات البوتاسيوم أو الماغنيسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمشاكل كبدية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدم تحمل اللاكتوز (سكر الحليب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبقت إصابتك أو قد تكون مصاباً حالياً بعدوى الالتهاب الكبدي ب. وهذا لأن سبرايسل قد يؤدي إلى معاودة الإصابة بعدوى الالتهاب الكبدي ب التي قد تؤدي إلى الوفاة في بعض الحالات. وسيقوم الطبيب بفحص المريض بعناية للتأكد من عدم وجود أعراض لهذه العدوى قبل بدء العلاج.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">لا يُعرف إذا ما كان سبرايسل آمناً وفعالاً للأطفال الذين يقل عمرهم عن عام واحد.</p><p dir="RTL"><strong>الأدوية الأخرى وسبرايسل</strong></p><p dir="RTL"><strong>أخبر مقدم الرعاية الصحية بجميع الأدوية التي تتناولها، </strong>بما في ذلك جميع الأدوية التي تُصرف بوصفة طبية والتي تُصرف بدونها، والفيتامينات، ومضادات الحموضة والمكملات العشبية. <strong>إذا كنت تتناول مضاداً للحموضة، عليك تناوله قبل ساعتين أو بعد ساعتين من تلقي جرعة سبرايسل.</strong></p><p>&nbsp;</p><p dir="RTL">اﻟﻛﺑد ھو اﻟﻌﺿو اﻟرﺋﯾﺳﻲ اﻟذي ﯾﺗﻌﺎﻣل ﻣﻊ ﺳﺑراﯾﺳل. ﺑﻌﺾ اﻷدوﯾﺔ ﻗﺪ ﺗﺘﺪاﺧﻞ ﻣﻊ ﺗﺄﺛﯿﺮ ﺳﺒﺮاﯾﺴﻞ ﻋﻨﺪﻣﺎ ﺗﺆﺧﺬ ﻣﻌاً.</p><p>&nbsp;</p><p dir="RTL"><strong>لا تستخدم هذه الأدوية مع سبرايسل:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كيتوكونازول، إيتراكونازول - <strong>لعلاج الفطريات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إريثرومايسين، كلاريثرومايسين، تيليثرومايسين - <strong>مضادات حيوية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير - <strong>مضاد للفيروسات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين، كربامازيبين، فينوباربيتال - <strong>لعلاج الصرع</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين - <strong>لعلاج السل</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فاموتيدين، أوميبرازول - <strong>لتثبيط حمض المعدة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز - وهي مستحضر عشبي يصرف بدون وصفة طبية، وتستخدم لعلاج <strong>الاكتئاب</strong> وحالات مرضية أخرى (تعرف أيضاً باسم <em>العرن المثقوب</em>)</p><p>&nbsp;</p><p dir="RTL"><strong>لا تتناول </strong>الأدوية التي تبطل مفعول حمض المعدة مثل (<strong>مضادات الحموضة</strong> مثل هيدروكسيد الألومنيوم أو هيدروكسيد الماغنيسيوم) حتى <strong>ساعتين قبل أو بعد تلقي سبرايسل.</strong></p><p>&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك </strong>إذا كنت تتلقى <strong>أدوية لمنع تخثر الدم أو منع الجلطات.</strong></p><p dir="RTL"><strong>تناول سبرايسل مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناول سبرايسل مع الطعام أو بدونه.</p><p dir="RTL">لا ينبغي تناول عصير الجريب فروت أثناء العلاج بسبرايسل.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للحمل، اطلبي المشورة من طبيبك أو الصيدلي قبل تناول هذا الدواء. فقد يضر سبرايسل بجنينك.</p><p dir="RTL"><strong>السيدات القادرات على الإنجاب:</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ألا تصبحي حاملاً خلال فترة العلاج بسبرايسل.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليكِ استخدام وسيلة منع حمل فعالة خلال فترة العلاج ولمدة 30 يوماً بعد جرعتك الأخيرة من سبرايسل.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري مقدم الرعاية الصحية على الفور إذا ما أصبحتِ حاملاً أو كنتِ تفكرين في الحمل خلال العلاج بدواء سبرايسل.</p><p dir="RTL"><strong>أزواج السيدات القادرات على الإنجاب:</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب استخدام وسيلة منع حمل فعالة خلال فترة العلاج ولمدة 30 يوماً بعد جرعتك الأخيرة من سبرايسل.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على زوجتك الاتصال بمقدم الرعاية الصحية إذا أصبحت حاملاً أو تعتقد أنها قد تكون حاملاً خلال فترة العلاج بسبرايسل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ ترضعين رضاعة طبيعية أو تخططين لذلك، لا يُعرَف ما إذا كان سبرايسل يمر إلى حليب الثدي. لا ترضعي رضاعة طبيعية خلال فترة العلاج بسبرايسل ولمدة أسبوعين بعد الجرعة الأخيرة من سبرايسل.</p><p dir="RTL"><strong>يجب على النساء الحوامل عدم التعامل مع أقراص سبرايسل المسحوقة أو المكسورة.</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لم تُجر دراسات على التأثير على القدرة على قيادة السيارات وتشغيل الآلات. ويجب التنبيه على المرضى بأنهم قد يختبرون تفاعلات ضائرة مثل الدوخة أو غشاوة الإبصار خلال فترة العلاج بمادة داساتينيب. لذلك يوصى بتوخي الحذر عند قيادة السيارة أو تشغيل الآلات.</p><p dir="RTL"><strong>يحتوي سبرايسل على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك تعاني من حساسية مفرطة لبعض أنواع السكر، اتصل بطبيبك قبل تناول هذا المنتج الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سبرايسل دواء مضاد للأورام. ويجب توخي الحذر عند التعامل مع سبرايسل لتقليل مخاطر التعرض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يبدأ العلاج بسبرايسل ويراقب تحت إشراف طبيب خبير في العوامل المضادة للأورام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأشخاص الذين لا يتناولون سبرايسل يجب ألا يتعرضوا له.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب ابتلاع الأقراص كاملة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي كسر الأقراص أو سحقها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول سبرايسل على النحو الذي وصفه مقدم الرعاية الصحية بدقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقوم مقدم الرعاية الصحية بتغيير جرعتك من سبرايسل أو يضطر إلى وقف استعماله مؤقتاً. <strong>لا تغير الجرعة الموصوفة لك ولا تتوقف عن استعمال سبرايسل بدون التحدث أولاً مع مقدم الرعاية الصحية.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم سبرايسل مرة واحدة في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول سبرايسل مع الطعام أو بدونه، سواء في الصباح أو المساء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع أقراص سبرايسل كاملة. لا تسحق الأقراص أو تكسرها أو تقطعها أو تمضغها.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يكن بإمكان طفلك ابتلاع الأقراص كاملة، تحدث إلى مقدم الرعاية الصحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي تناول عصير الجريب فروت أثناء العلاج بسبرايسل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تناول إحدى جرعات سبرايسل، تناول جرعتك التالية المقررة في موعدها المعتاد. ولا تتناول جرعتين في آن واحد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تناول مقداراً أكبر مما ينبغي من سبرايسل، اتصل بمقدم الرعاية الصحية أو توجه فوراً إلى قسم الطوارئ في أقرب مستشفى.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لسبرايسل أن يسبب آثاراً جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع.</p><p dir="RTL"><strong>قد يتسبب سبرايسل في حدوث آثار جانبية خطيرة، تتضمن:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نقص أعداد خلال الدم.</strong> إن نقص أعداد خلال الدم شائع مع استخدام سبرايسل وقد يكون النقص شديداً ويشمل نقص أعداد خلال الدم الحمراء (أنيميا)، ونقص أعداد خلايا الدم البيضاء (نقص الخلايا المتعادلة)، ونقص عدد الصفيحات الدموية (قلة الصفائح الدموية). سيجري لك مقدم الرعاية الصحية تحاليل دم لقياس أعداد خلايا الدم لديك بصفة منتظمة أثناء علاجك باستعمال سبرايسل. اتصل فوراً بمقدم الرعاية الصحية إذا حدثت لديك حمى أو أي علامات تدل على العدوى أثناء علاجك بسبرايسل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>النزف.</strong> مشكلات النزف شائعة مع سبرايسل. وفي بعض الأوقات يمكن أن تكون مشكلات النزف خطيرة وتؤدي إلى الوفاة. اتصل بمقدم الرعاية الصحية فوراً إذا حدث لديك:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف غير معتاد أو كدمة في جلدك</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلون البراز باللون الأحمر أو باللون الداكن الشبيه بالقطران</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في الإدراك أو صداع أو تغير في الكلام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قد يحتجز جسمك كمية كبيرة من السوائل (احتجاز السوائل).</strong> إن احتجاز السوائل شائع مع استخدام سبرايسل وقد يكون حاداً في بعض الأوقات. وفي الحالات الحادة، قد تتراكم السوائل في الغشاء المبطن للرئتين، أو الكيس المحيط بالقلب، أو في تجويف البطن. اتصل فوراً بمقدم الرعاية الصحية إذا حدث لك أي من هذه الأعراض خلال فترة استعمال سبرايسل:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في كل أنحاء جسمك</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس خصوصاً أثناء النشاط البدني المنخفض أو في أوقات الراحة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال جاف</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر عند أخذ نفس عميق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل في القلب والأوعية الدموية</strong><strong> </strong><strong>(قلب وعائية).</strong> قد يؤدي سبرايسل إلى حدوث مشاكل في القلب، تتضمن خلل في معدل ضربات القلب، أو نوبة قلبية، أو سكتات صغيرة قد تدوم فقط لبضع دقائق أو بضع ساعات، تسمى نوبات إقفارية عابرة (TIAs)، وهي كثيراً ما تكون علامة تحذيرية أنك معرض لسكتات أكثر خطورة. سيراقب مقدم الرعاية الصحية مستويات البوتاسيوم والماغنيسيوم في دمك، ووظيفة قلبك.</p><p dir="RTL">اطلب المساعدة الطبية على الفور إذا ظهرت عليك أي من الأعراض التالية خلال فترة العلاج بسبرايسل:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بتسارع أو خلل في ضربات القلب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات إبصارية قد تدوم لفترة قصيرة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التلعثم في الحديث</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع ضغط الدم الشرياني الرئوي (</strong><strong>PAH</strong><strong>).</strong> قد يؤدي سبرايسل إلى ارتفاع ضغط الدم في أوعية رئتيك. وقد يحدث ارتفاع الضغط الشرياني الرئوي في أي وقت خلال فترة علاجك بسبرايسل. فيجب على مقدم الرعاية الصحية فحص قلبك ورئتيك قبل وخلال فترة علاجك بسبرايسل. اتصل بمقدم الرعاية الصحية فوراً إذا حدث لديك ضيق تنفس أو إعياء أو تورم في جسمك بأكمله (احتجاز السوائل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تفاعلات جلدية حادة.</strong> قد يحدث سبرايسل تفاعلات بالجلد قد تكون حادة في بعض الأحيان. احصل على المساعدة الطبية على الفور إذا ظهر لديك تفاعلات بالجلد مصحوبة بارتفاع في درجة الحرارة أو التهاب الفم أو الحلق أو ظهور بثور متقرحة أو تقشر في الجلد أو داخل الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>متلازمة انحلال الورم (</strong><strong>TLS</strong><strong>).</strong> يؤدي الانحلال السريع لخلايا السرطان إلى الإصابة بمتلازمة انحلال الورم (TLS) التي قد تسبب الإصابة بالفشل الكلوي والحاجة إلى غسيل الكلى، وعدم انتظام ضربات القلب. وقد يجري مقدم الرعاية الصحية اختبارات دم لمعرفة إذا ما أصبت بمتلازمة انحلال الورم (TLS) أم لا. اتصل بمقدم الرعاية الصحية أو اطلب المساعدة الطبية على الفور إذا ظهرت عليك أي من هذه الأعراض خلال العلاج بدواء سبرايسل:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرع</p></td></tr></tbody></table><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تباطؤ نمو الأطفال وتطورهم. </strong>ظهرت آثار على نمو العظام وتطورها في الأطفال الذين يعالجون بدواء سبرايسل وقد تكون في بعض الأحيان شديدة. سيراقب مقدم الرعاية الصحية نمو عظام طفلك وتطورها أثناء العلاج بدواء سبرايسل. اطلب مساعدة طبية على الفور إذا شعر طفلك بألم في العظام.</p><p dir="RTL">الآثار الجانبية الأكثر شيوعاً لدواء سبرايسل لدى البالغين والأطفال الذين يتلقون سبرايسل وحده تتضمن:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:643px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإجهاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عضلي</p><p dir="LTR">&nbsp;</p></td></tr></tbody></table><p dir="RTL">الآثار الجانبية الأكثر شيوعاً لدواء سبرايسل لدى البالغين والأطفال الذين يتلقون سبرايسل إلى جانب العلاج الكيميائي تتضمن:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم وألم واحمرار بطانة الفم، الحلق، المعدة والأمعاء (التهاب الغشاء المخاطي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم البيضاء المصحوب بحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عضلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم منطقة المعدة (البطن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="LTR">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإجهاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب بمعدل غير طبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر أو وخز في اليدين والقدمين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالارتباك أو التوهان</p><p dir="LTR">&nbsp;</p></td></tr></tbody></table><p dir="RTL">قد يسبب سبرايسل مشكلات تتعلق بالخصوبة عند الرجال والسيدات. تحدث إلى مقدم الرعاية الصحية إذا كان هذا الأمر يقلقك.</p><p dir="RTL"><strong>آثار جانبية شائعة جداً (قد تؤثر على أكثر من 1 من كل 10 أشخاص) </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العدوى: </strong>(تشمل العدوى البكتيرية، والفيروسية، والفطرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>القلب والرئتان: </strong>ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل هضمية: </strong>إسهال، شعور بالتوعك (غثيان، قيء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجلد، الشعر، العين، عامة: </strong>طفح جلدي، حمى، تورم حول الوجه واليدين والقدمين، صداع، شعور بالتعب أو الضعف، نزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ألم: </strong>ألم في العضلات (خلال فترة العلاج أو بعد الانقطاع عن العلاج)، ألم البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قد يظهر في الاختبارات: </strong>نقص عدد الصفيحات الدموية، نقص عدد خلايا الدم البيضاء (نقص الخلايا المتعادلة)، فقر الدم (أنيميا)، سوائل حول الرئة</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر على 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>عدوى: </strong>التهاب رئوي، عدوى بفيروس الهربس (بما في ذلك الفيروس المضخم للخلايا - CMV)، عدوى المسالك التنفسية العلوية، عدوى خطيرة في الدم أو الأنسجة (قد تؤدي إلى حالات وفاة غير شائعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>القلب والرئتان: </strong>خفقان، ضربات قلب غير منتظمة، فشل قلبي احتقاني، ضعف عضلة القلب، ارتفاع ضغط الدم، ارتفاع ضغط الدم في الرئتين، سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل هضمية: </strong>اضطرابات في الشهية، خلل في حاسة التذوق، انتفاخ البطن بالغازات، التهاب القولون، الإمساك، حرقة المعدة، قروح الفم، زيادة الوزن، نقص الوزن، التهاب المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجلد، الشعر، العين، عامة: </strong>تنميل الجلد، حكة، جفاف الجلد، حب الشباب، التهاب الجلد، طنين مستمر في الأذنين، سقوط الشعر، تعرق مفرط، خلل في الإبصار (يشمل غشاوة الإبصار واضطراب الإبصار)، جفاف العين، تورم دموي، اكتئاب، أرق، توهج، دوخة، كدمات (تكدم)، فقدان الشهية، نعاس، وذمة عمومية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ألم: </strong>ألم في المفاصل، ضعف عضلي، ألم في الصدر، ألم حول اليدين والقدمين، قشعريرة، تيبس في العضلات والمفاصل، تشنج عضلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قد يظهر في الاختبارات: </strong>سائل حول القلب، سائل في الرئتين، اضطراب النظم القلبي، نقص خلايا الدم المتعادلة مع حمى، نزف من القناة الهضمية، ارتفاع مستويات حمض اليوريك في الدم</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر على 1 من كل 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>القلب والرئتان: </strong>نوبة قلبية (قد تؤدي إلى الوفاة)، التهاب في بطانة القلب (الكيس الليفي المحيط بالقلب)، اضطراب ضربات القلب، ألم في الصدر بسبب نقص الدم المغذي للقلب (ذبحة صدرية)، انخفاض ضغط الدم، ضيق المسالك الهوائية مما قد يسبب صعوبات في التنفس، ربو، ارتفاع ضغط الدم في شرايين (الأوعية الدموية) الرئة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل هضمية: </strong>التهاب البنكرياس، قرحة هضمية، التهاب المريء، انتفاخ البطن، شرخ في جلد القناة الشرجية، صعوبة في البلع، التهاب الحويصلة المرارية، انسداد القنوات الصفراوية، مرض الارتجاع المعدي المريئي (هو مرض ارتجاع الحمض المعدي وغيره من محتويات المعدة إلى الحلق)</p><p dir="RTL">&middot;&nbsp; <strong>الجلد، الشعر، العين، عامة: </strong>حساسية مفرطة تشمل حدوث كتل حمراء مؤلمة في الجلد (الحمامي العقدية)، قلق، تشويش، تقلبات مزاجية، نقص الرغبة الجنسية، إغماء، رعشة، التهاب العين مما يسبب الاحمرار أو الألم، مرض جلدي يتصف بوجود لويحات محددة حمراء مؤلمة مع حدوث حمى مفاجئة وارتفاع عدد خلايا الدم البيضاء (اعتلال جلدي حاد مصحوب بحمى وزيادة في عدد خلايا الدم البيضاء)، فقدان السمع، حساسية للضوء، ضعف البصر، زيادة تدمع العينين، خلل في لون الجلد، التهاب النسيج الدهني تحت الجلد، قرحة جلدية، بثور جلدية، خلل في الأظافر، خلل في الشعر، خلل باليد وبالقدم، فشل كلوي، تواتر البول، تضخم الثدي في الرجال، عدم انتظام الطمث، ضعف عام وتوعك، قصور الغدة الدرقية، واضطراب التوازن عند المشي، تنخر العظم (مرض ينخفض به تدفق الدم للعظام، مما قد يسبب ترققها وموتها)، والتهاب المفاصل، وذمة جلدية أخرى في أي مكان على الجسم</p><p dir="RTL">&middot;&nbsp; <strong>ألم: </strong>التهاب الأوردة بما قد يؤدي إلى حدوث احمرار، وإيلام، وتورم، التهاب الأوتار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الدماغ: </strong>فقدان الذاكرة</p><p dir="RTL">&middot;&nbsp; <strong>قد يظهر في الاختبارات: </strong>خلل في نتائج اختبارات الدم وربما ضعف في الوظيفة الكلوية بسبب النفايات الناتجة عن موت الورم (متلازمة انحلال الورم)، نقص مستويات الألبومين في الدم، انخفاض في عدد الخلايا اللمفاوية (نوع من كريات الدم البيضاء) في الدم، ارتفاع مستوى الكوليسترول في الدم، تضخم العقد اللمفاوية، نزيف في الدماغ، عدم انتظام النشاط الكهربي للقلب، تضخم القلب، التهاب الكبد، بروتين في البول، ارتفاع كرياتين فوسفوكيناز (إنزيم يوجد أساساً في القلب والدماغ والعضلات الهيكلية)، زيادة التروبونين (إنزيم يوجد أساساً في اللب، والعضلات الهيكلية)، زيادة في ناقلة البيتيد غاما غلوتاميل (إنزيم يوجد أساساً في الكبد)، سائل يشبه الحليب حول الرئتين (الكيلوس)</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض جانبية نادرة (قد تؤثر على 1 من كل 1000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>القلب والرئتان: </strong>تضخم البطين الأيمن للقلب، التهاب عضلة القلب، مجموعة من الحالات الناتجة عن انسداد الدم المغذي لعضلة القلب (المتلازمة التاجية الحادة)، سكتة قلبية (توقف ضخ الدم من القلب)، مرض الشريان التاجي، التهاب الغشاء المحيط بالقلب والرئة، تجلط الدم، تجلط الدم في الرئة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل هضمية: </strong>فقدان المواد الغذائية الحيوية مثل البروتين من القناة الهضمية، انسداد الأمعاء، الناسور حول الشرج (فتحة غير طبيعية من الشرج إلى سطح الجلد حوله)، ضعف في وظائف الكلى، داء السكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجلد، الشعر، العين، عامة: </strong>تشنج، التهاب العصب البصري مما قد يؤدي إلى فقدان الإبصار بشكل كامل أو جزئي، بقع زرقاء بنفسجية على الجلد، ارتفاع غير طبيعي في وظائف الغدة الدرقية، التهاب الغدة الدرقية، الرنح (حالة تتعلق بضعف التنسيق العضلي)، اضطرابات في المشية، التهاب الأوعية الدموية لسطح الجلد، تليف الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الدماغ: </strong>سكتة دماغية، نوبة مؤقتة من خلل الوظيفة العصبية بسبب انقطاع سريان الدم، شلل العصب الوجهي، خرف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجهاز المناعي: </strong>تفاعلات تحسسية شديدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الاضطرابات العضلية الهيكلية واضطرابات الأنسجة الضامة: </strong>تأخر اندماج النهايات المستديرة التي تشكل المفاصل (المشاش)، بطء أو تأخر النمو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قد يظهر في الاختبارات: </strong>نقص إنتاج خلايا الدم الحمراء</p><p>&nbsp;</p><p dir="RTL">أخبر مقدم الرعاية الصحية إذا ظهرت عليك أي آثار جانبية مقلقة أو لا تزول. هذه ليست جميع الآثار الجانبية المحتملة لسبرايسل.</p><p dir="RTL">اتصل بطبيبك للحصول على استشارة طبية بشأن الآثار الجانبية.</p><p dir="RTL">في حال أصبحت أي من هذه الأعراض الجانبية خطرة، أو إن لاحظت أي أعراض جانبية غير مذكورة في هذه النشرة، يرجى إخبار مقدم الرعاية الصحية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سبرايسل دواء مضاد للأورام. ويجب توخي الحذر عند التعامل مع سبرايسل لتقلل مخاطر التعرض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأشخاص الذين لا يتناولون سبرايسل يجب ألا يتعرضوا له.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب نقل الدواء وتخزينه في الحاوية الأصلية أو الشريط الأصلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لإعطاء الدواء، استخدم قفازات واغسل يديك جيداً قبل إعطاء الدواء وبعده. وإن لم يتم ارتداء القفازات، يقلب القرص مباشرةً من العبوة/الشريط إلى داخل كوب طبي يمكن التخلص منه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي تقسيم الأقراص أو كسرها أو سحقها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتدِ قفازات من اللاتكس أو النيتريل عند التعامل مع الأقراص التي سحقت أو كسرت عرضياً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على النساء الحوامل تجنب التعرض للأقراص المغلفة المسحوقة أو المكسورة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب توخي الحذر في التعامل مع الأقراص المكسورة أو المسحوقة. وتجنب ملامسة سبرايسل للجلد أو الأغشية المخاطية بشكل مباشر. وإن حدث مثل هذا التلامس، يجب غسل الموضع جيداً بالماء والصابون، وشطف العينين جيداً بماء معقم أو ماء عادي إذا كان الماء المعقم غير متوفر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على أفراد الأسرة استخدام قفازات عند التعامل مع الغسيل أو تنظيف داخل المراحيض أو حولها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن أمكن، استخدم حماماً منفصلاً عن حمام بقية أفراد الأسرة. أغلق الغطاء قبل شطف المرحاض بالدفق واشطفه مرتين بعد كل استخدام من قبل المريض، لمدة 48 ساعة بعد تلقي العلاج الكيميائي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب غسل البياضات غسلاً مزدوجاً وتغسل بشكل منفصل عن غسيل الأسرة الآخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ سبرايسل وجميع الأدوية بعيداً عن متناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ سبرايسل في درجة حرارة الغرفة بين 20 درجة مئوية و25 درجة مئوية. ولا تخزن سبرايسل في درجة حرارة تزيد عن 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك طبيبك أن تتوقف عن تناول سبرايسل أو انتهت صلاحية دواءك. لا تتخلص منه في ماء الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها، أو أعدها إلى الصيدلي الذي سيقوم بإتلافها وفقاً لإرشادات التخلص من المواد الخطرة. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بالدواء فقط إذا أخبرك طبيبك بذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة: داساتينيب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات غير الفعالة لأقراص سبرايسل: لاكتوز مونوهيدرات، سيليلوز دقيق التبلور، كروسكارميلوز صوديوم، هيدروكسي بروبيل سيليلوز، ستيارات ماغنيسيوم. ويتكون غلاف القرص من هيبروميلوز، ثاني أكسيد التيتانيوم، بولي إيثيلين جليكول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر أقراص سبرايسل كما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 مجم، قرص مغلف أبيض إلى مائل للأبيض، ثنائي التحدب، مستدير، مطبوع على أحد جانبيه العلامة &quot;BMS&quot; وعلى الجانب الآخر الرقم &quot;527&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50 مجم، قرص مغلف أبيض إلى مائل للأبيض، ثنائي التحدب، بيضاوي، مطبوع على أحد جانبيه العلامة &quot;BMS&quot; وعلى الجانب الآخر الرقم &quot;528&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 70 مجم، قرص مغلف أبيض إلى مائل للأبيض، ثنائي التحدب، مستدير، مطبوع على أحد جانبيه العلامة &quot;BMS&quot; وعلى الجانب الآخر الرقم &quot;524&quot;.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعة وصاحبة ترخيص المنتج</strong></p><p dir="RTL"><strong>مالك حق التسويق: </strong></p><p dir="RTL">شركة بريستول مايرز سكويب</p><p dir="RTL">برنستون، نيوجيرسي 08543 الولايات المتحدة الأمريكية</p><p dir="RTL"><strong>تم التصنيع بواسطة:</strong></p><p dir="RTL">أسترازينيكا فارماسيوتيكالز إل بي</p><p dir="RTL">4601 الطريق السريع 62 شرق</p><p dir="RTL">مونت فيرنون، إنديانا 47620، الولايات المتحدة الأمريكية</p><p>&nbsp;</p><p dir="RTL">شركة باثيون،</p><p dir="RTL">2100 سينتكس كورت، ميسيساغا،</p><p dir="RTL">أونتاريو، L5N 7K9</p><p dir="RTL">كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPRYCEL®
(dasatinib)
Tablets
20 mg film-coated tablet
50 mg film-coated tablet
70 mg film-coated tablet

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPRYCEL (dasatinib) is a kinase inhibitor. The chemical name for dasatinib is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate. The molecular formula is C22H26CN7O2S · H2O, which corresponds to a formula weight of 506.02 (monohydrate). The anhydrous free base has a molecular weight of 488.01. Dasatinib has the following chemical structure:
 
Dasatinib is a white to off-white powder. The drug substance is insoluble in water and slightly soluble in ethanol and methanol.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPRYCEL (dasatinib) Tablets are available as 20-mg, 50-mg, and 70-mg white to off-white, biconvex, film-coated tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SPRYCEL (dasatinib) is indicated for the treatment of adult patients with</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+&nbsp;ALL) with resistance or intolerance to prior therapy.</p><p>SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ph+ CML in chronic phase.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; newly diagnosed Ph+ ALL in combination with chemotherapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General</p><p>SPRYCEL treatment must be initiated and monitored under the supervision of a physician experienced in antineoplastic agents.</p><p>Method of Administration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPRYCEL is an antineoplastic drug. Follow applicable special handling and disposal procedures [<em>see Special precautions for disposal and other handling (6.6)].</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablets should be swallowed whole.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets should not be broken or crushed, if possible. This might produce powder that can contaminate workplace surfaces.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If tablet must be cut or crushed, this should be done by a professionally trained person experienced in safe handling of hazardous drugs using appropriate equipment and safety procedures.</p><p><strong>&nbsp;</strong></p><p>Dosage of SPRYCEL in Adult Patients</p><p>The recommended starting dosage of SPRYCEL for chronic phase CML in adults is 100 mg administered orally once daily. The recommended starting dosage of SPRYCEL for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+&nbsp;ALL in adults is 140&nbsp;mg administered orally once daily. Tablets should not be crushed, cut, or chewed; they should be swallowed whole. SPRYCEL can be taken with or without a meal, either in the morning or in the evening.</p><p>Dosage of SPRYCEL in Pediatric Patients with CML or Ph+ ALL</p><p>The recommended starting dosage for pediatrics is based on body weight as shown in Table 1. The recommended dose should be administered orally once daily with or without food. Recalculate the dose every 3 months based on changes in body weight, or more often if necessary.</p><p><strong>Do not crush, cut or chew tablets. Swallow tablets whole.</strong> There are additional administration considerations for pediatric patients who have difficulty swallowing tablets whole <em>[see Undesirable effects (4.8) and Pharmacokinetic properties (5.2)].</em></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="2"><p><strong>Table 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dosage of SPRYCEL for Pediatric Patients<sup>a</sup></strong></p></td></tr><tr><td><p><strong>Body Weight (kg)</strong><sup>b</sup><strong> </strong></p></td><td><p><strong>Daily Dose (mg)</strong></p></td></tr></thead><tbody><tr><td><p>10 to less than 20</p></td><td><p>40 mg</p></td></tr><tr><td><p>20 to less than 30</p></td><td><p>60 mg</p></td></tr><tr><td><p>30 to less than 45</p></td><td><p>70 mg</p></td></tr><tr><td><p>at least 45</p></td><td><p>100 mg</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For pediatric patients with Ph+ ALL, begin SPRYCEL therapy on or before day 15 of induction chemotherapy, when diagnosis is confirmed and continue for 2 years.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet dosing is not recommended for patients weighing less than 10 kg.</p><p>&nbsp;</p><p>Refer to section below for recommendations on dose escalation in adults with CML and Ph+ ALL, and pediatric patients with CML.</p><p>Dose Modification</p><p>Strong CYP3A4 Inducers</p><p>Avoid the use of concomitant strong CYP3A4 inducers and St. John&rsquo;s wort. If patients must be coadministered a strong CYP3A4 inducer, consider a SPRYCEL dose increase. If the dose of SPRYCEL is increased, monitor the patient carefully for toxicity <em>[see Interaction with other medicinal products and other forms of interaction (4.5)]</em>.</p><p>Strong CYP3A4 Inhibitors</p><p>Avoid the use of concomitant strong CYP3A4 inhibitors and grapefruit juice. Recommend selecting an alternate concomitant medication with no or minimal enzyme inhibition potential, if possible. If SPRYCEL must be administered with a strong CYP3A4 inhibitor, consider a dose decrease to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40 mg daily for patients taking SPRYCEL 140 mg daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 mg daily for patients taking SPRYCEL 100&nbsp;mg daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 mg daily for patients taking SPRYCEL 70 mg daily.</p><p>For patients taking SPRYCEL 60 mg or 40 mg daily, consider interrupting SPRYCEL, until the inhibitor is discontinued. Allow a washout period of approximately 1 week after the inhibitor is stopped before reinitiating SPRYCEL.</p><p>These reduced doses of SPRYCEL are predicted to adjust the area under the curve (AUC) to the range observed without CYP3A4 inhibitors; however, clinical data are not available with these dose adjustments in patients receiving strong CYP3A4 inhibitors. If SPRYCEL is not tolerated after dose reduction, either discontinue the strong CYP3A4 inhibitor or interrupt SPRYCEL until the inhibitor is discontinued. Allow a washout period of approximately 1 week after the inhibitor is stopped before the SPRYCEL dose is increased <em>[see Interaction with other medicinal products and other forms of interaction (4.5)].</em></p><p>Dose Escalation in Adults with CML and Ph+ ALL, and Pediatric Patients with CML</p><p>For adult patients with CML and Ph+&nbsp;ALL, consider dose escalation to 140 mg once daily (chronic phase CML) or 180 mg once daily (advanced phase CML and Ph+&nbsp;ALL) in patients who do not achieve a hematologic or cytogenetic response at the recommended starting dosage. For pediatric patients with CML, consider dose escalation to 120 mg once daily (see Table 2 below). Dose escalation is not recommended for pediatric patients with Ph+ ALL, where SPRYCEL is administered in combination with chemotherapy.</p><p>Escalate the SPRYCEL dose as shown in Table 2 in pediatric patients with chronic phase CML who do not achieve a hematologic or cytogenetic response at the recommended starting dosage.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose Escalation for Pediatric CML</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Formulation</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Dose (maximum dose per day)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Starting Dose</strong></p></td><td style="vertical-align:top"><p><strong>Escalation</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Tablets</strong></p></td><td style="vertical-align:top"><p>40 mg</p></td><td style="vertical-align:top"><p>50 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>60 mg</p></td><td style="vertical-align:top"><p>70 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>70 mg</p></td><td style="vertical-align:top"><p>90 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>120 mg</p></td></tr></tbody></table><p>&nbsp;</p><p>Dose Adjustment for Adverse Reactions</p><p>Myelosuppression</p><p>In clinical studies, myelosuppression was managed by dose interruption, dose reduction, or discontinuation of study therapy. Hematopoietic growth factor has been used in patients with resistant myelosuppression. Guidelines for dose modifications for adult and pediatric patients are summarized in Tables 3 and 4, respectively.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose Adjustments for Neutropenia and Thrombocytopenia in Adults</p></td></tr></thead><tbody><tr><td><p>Chronic Phase CML</p><p>(starting dose 100 mg once daily)</p></td><td><p>ANC* &lt;0.5 &times; 109/L</p><p>or</p><p>Platelets &lt;50 &times; 109/L</p></td><td style="vertical-align:top"><p>1.&nbsp; Stop SPRYCEL until ANC &ge;1.0 &times; 109/L and platelets &ge;50 &times; 109/L.</p><p>2.&nbsp; Resume treatment with SPRYCEL at the original starting dose if recovery occurs in &le;7&nbsp;days.</p><p>3. &nbsp;If platelets &lt;25 &times; 10<sup>9</sup>/L or recurrence of ANC &lt;0.5 &times; 10<sup>9</sup>/L for &gt;7 days, repeat Step 1 and resume SPRYCEL at a reduced dose of 80 mg once daily for second episode. For third episode, further reduce dose to 50 mg once daily (for newly diagnosed patients) or discontinue SPRYCEL (for patients resistant or intolerant to prior therapy including imatinib).</p></td></tr><tr><td><p>Accelerated Phase CML, Blast Phase CML and Ph+&nbsp;ALL</p><p>(starting dose 140 mg once daily)</p></td><td><p>ANC* &lt;0.5 &times; 109/L</p><p>or</p><p>Platelets &lt;10 &times; 109/L</p></td><td style="vertical-align:top"><p>1.&nbsp; Check if cytopenia is related to leukemia (marrow aspirate or biopsy).</p><p>2.&nbsp; If cytopenia is unrelated to leukemia, stop SPRYCEL until ANC &ge;1.0 &times; 109/L and platelets &ge;20 &times; 109/L and resume at the original starting dose.</p><p>3.&nbsp; If recurrence of cytopenia, repeat Step 1 and resume SPRYCEL at a reduced dose of 100&nbsp;mg once daily (second episode) or 80 mg once daily (third episode).</p><p>4.&nbsp; If cytopenia is related to leukemia, consider dose escalation to 180 mg once daily.</p></td></tr><tr><td colspan="3"><p>*&nbsp;&nbsp; ANC: absolute neutrophil count</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:647px"><thead><tr><td colspan="5"><p><strong>Table 4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose Adjustments for Neutropenia and Thrombocytopenia in Pediatric Patients with Ph+ CML</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="4"><p><strong>Dose (maximum dose per day)</strong></p></td></tr></thead><tbody><tr><td rowspan="7"><p>1. If cytopenia persists for more than 3 weeks, check if cytopenia is related to leukemia (marrow aspirate or biopsy).</p><p>2. If cytopenia is unrelated to leukemia, stop SPRYCEL until ANC* &ge;1.0 &times; 10<sup>9</sup>/L and platelets &ge;75 &times; 10<sup>9</sup>/L and resume at the original starting dose or at a reduced dose.</p><p>3. If cytopenia recurs, repeat marrow aspirate/biopsy and resume SPRYCEL at a reduced dose.</p></td><td><p>&nbsp;</p></td><td><p><strong>Original Starting Dose</strong></p></td><td><p><strong>One-Level Dose Reduction</strong></p></td><td><p><strong>Two-Level Dose Reduction</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>Tablets</strong></p></td><td><p>40 mg</p></td><td><p>20 mg</p></td><td><p>**</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>60 mg</p></td><td><p>40 mg</p></td><td><p>20 mg</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>70 mg</p></td><td><p>60 mg</p></td><td><p>50 mg</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>100 mg</p></td><td><p>80 mg</p></td><td><p>70 mg</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p>*&nbsp;&nbsp; ANC: absolute neutrophil count</p><p>**&nbsp;&nbsp; lower tablet dose not available</p></td></tr></tbody></table><p>For pediatric patients with chronic phase CML, if Grade &ge; 3 neutropenia or thrombocytopenia recurs during complete hematologic response (CHR), interrupt SPRYCEL and resume at a reduced dose. Implement temporary dose reductions for intermediate degrees of cytopenia and disease response as needed.</p><p>For pediatric patients with Ph+ ALL, if neutropenia and/or thrombocytopenia result in a delay of the next block of treatment by more than 14 days, interrupt SPRYCEL and resume at the same dose level once the next block of treatment is started. If neutropenia and/or thrombocytopenia persist and the next block of treatment is delayed another 7 days, perform a bone marrow assessment to assess cellularity and percentage of blasts. If marrow cellularity is &lt;10%, interrupt treatment with SPRYCEL until ANC &gt;500/&mu;L (0.5 x 10<sup>9</sup>/L), at which time treatment may be resumed at full dose. If marrow cellularity is &gt;10%, resumption of treatment with SPRYCEL may be considered.</p><p>Non-Hematologic Adverse Reactions</p><p>For adults with Ph+ CML and ALL, and pediatric patients with Ph+ CML, if a severe non-hematologic adverse reaction develops with SPRYCEL use, treatment must be withheld until the adverse reaction has resolved or improved. Thereafter, treatment can be resumed as appropriate at a reduced dose depending on the severity and recurrence <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>For pediatric patients with Ph+ ALL, interrupt treatment for cases of grade <u>&gt;</u> 3 non-hematologic adverse reactions with the exception of liver function test abnormalities, and resume at a reduced dose when resolved to grade <u>&lt;</u>1. For elevated direct bilirubin over 5 times the institutional upper limit of normal (ULN), interrupt treatment until improvement to baseline or grade <u>&lt;</u>1. For elevated AST/ALT over 15 times the institutional ULN, interrupt treatment until improvement to baseline or grade &lt;1. For recurrent liver function test abnormalities as above, reduce the dose if this adverse reaction recurs after reinitiation of SPRYCEL. Dose reduction recommendations are described in Table 5.</p><table border="1" cellspacing="0" cellpadding="0" style="width:844px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="5" style="width:820px"><p><strong>Table 5: Dose Adjustments for Non-Hematologic Toxicities in Pediatric Patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="width:463px"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="width:357px"><p><strong>Dose (maximum dose per day)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="7" style="width:463px"><p>1. If a non-hematologic toxicity grade 2 occurs, consider interrupting SPRYCEL if no recovery despite symptomatic therapy; once recovered to grade &le;1, resume at the original starting dose. Resume SPRYCEL at a reduced dose for recurrent events.</p><p>2. If a non-hematologic toxicity grade 3 occurs, stop SPRYCEL until recovery to grade &le;1 and then resume at a reduced dose.</p><p>3. If direct bilirubin is &gt;5 ULN or AST/ALT &gt;15 ULN, interrupt SPRYCEL until recovery to grade &le;1 and then resume SPRYCEL at the original starting dose. Resume SPRYCEL at a reduced dose for recurrent events.</p></td><td style="width:62px"><p>&nbsp;</p></td><td style="width:100px"><p><strong>Original Starting Dose</strong></p></td><td style="width:91px"><p><strong>One-Level Dose Reduction</strong></p></td><td style="width:104px"><p><strong>Two-Level Dose Reduction</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="width:62px"><p>&nbsp;</p></td><td style="width:100px"><p><strong>&nbsp;</strong></p></td><td style="width:91px"><p><strong>&nbsp;</strong></p></td><td style="width:104px"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="width:62px"><p><strong>Tablets</strong></p></td><td style="width:100px"><p>40 mg</p></td><td style="width:91px"><p>20 mg</p></td><td style="width:104px"><p>**</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="width:62px"><p>&nbsp;</p></td><td style="width:100px"><p>60 mg</p></td><td style="width:91px"><p>40 mg</p></td><td style="width:104px"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="width:62px"><p>&nbsp;</p></td><td style="width:100px"><p>70 mg</p></td><td style="width:91px"><p>60 mg</p></td><td style="width:104px"><p>50 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="width:62px"><p>&nbsp;</p></td><td style="width:100px"><p>100 mg</p></td><td style="width:91px"><p>80 mg</p></td><td style="width:104px"><p>70 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="width:62px"><p>&nbsp;</p></td><td style="width:100px"><p>&nbsp;</p></td><td style="width:91px"><p>&nbsp;</p></td><td style="width:104px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="width:820px"><p>** lower tablet dose not available</p></td></tr></tbody></table><p>&nbsp;</p><p>Duration of Treatment</p><p>In clinical studies, treatment with SPRYCEL in adults and in pediatric patients with chronic phase CML was continued until disease progression or until no longer tolerated by the patient. The effect of stopping treatment on long-term disease outcome after the achievement of a cytogenetic response (including complete cytogenetic response [CCyR]) or major molecular response (MMR and MR4.5) has not been established.</p><p>In clinical in pediatric patients with Ph+ ALL was administered for a maximum duration of 2 years <em>[see Posology and method of administration (4.2) and Pharmacodynamic properties (5.1)].</em></p><p>SPRYCEL is a hazardous product. Follow applicable special handling and disposal procedures.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Myelosuppression</p><p>Treatment with SPRYCEL is associated with severe (NCI CTCAE Grade 3 or 4) thrombocytopenia, neutropenia, and anemia, which occur earlier and more frequently in patients with advanced phase CML or Ph+ ALL than in patients with chronic phase CML <em>[see Undesirable effects (4.8)].</em></p><p>In patients with chronic phase CML, perform complete blood counts (CBCs) every 2 weeks for 12 weeks, then every 3 months thereafter, or as clinically indicated. In patients with advanced phase CML or Ph+ ALL, perform CBCs weekly for the first 2 months and then monthly thereafter, or as clinically indicated.</p><p>In pediatric patients with Ph+ ALL treated with SPRYCEL in combination with chemotherapy, perform CBCs prior to the start of each block of chemotherapy and as clinically indicated. During the consolidation blocks of chemotherapy, perform CBCs every 2&nbsp;days until recovery</p><p>Myelosuppression is generally reversible and usually managed by withholding SPRYCEL temporarily and/or dose reduction<em> [see Posology and method of administration (4.2)</em>.</p><p>Bleeding-Related Events</p><p>SPRYCEL can cause serious and fatal bleeding. In all CML or Ph+ ALL clinical studies, Grade &ge; 3 central nervous system (CNS) hemorrhages, including fatalities, occurred in &lt;1% of patients receiving SPRYCEL. The incidence of Grade 3/4 hemorrhage occurred in 5.8% of adult patients and generally required treatment interruptions and transfusions. The incidence of Grade 5 hemorrhage occurred in 0.4% of adult patients. The most frequent site of hemorrhage was gastrointestinal <em>[see Undesirable effects (4.8)].</em> Most bleeding events in clinical studies were associated with severe thrombocytopenia. In addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction <em>in vitro</em>.</p><p>Concomitant medications that inhibit platelet function or anticoagulants may increase the risk of hemorrhage.</p><p>Fluid Retention</p><p>SPRYCEL may cause fluid retention <em>[see Undesirable effects (4.8)].</em> After 5 years of follow-up in the adult randomized newly diagnosed chronic phase CML study (n=258), Grade 3 or 4 fluid retention was reported in 5% of patients, including 3% of patients with Grade 3 or 4 pleural effusion. In adult patients with newly diagnosed or imatinib-resistant or -intolerant chronic phase CML, Grade 3 or 4 fluid retention occurred in 6% of patients treated with SPRYCEL at the recommended dose (n=548). In adult patients with advanced phase CML or Ph+ ALL treated with SPRYCEL at the recommended dose (n=304), Grade 3 or 4 fluid retention was reported in 8% of patients, including Grade 3 or 4 pleural effusion reported in 7% of patients. In pediatric patients with chronic phase CML, cases of Grade 1 or 2 fluid retention were reported in 10.3% of patients.</p><p>Evaluate patients who develop symptoms of pleural effusion or other fluid retention, such as new or worsened dyspnea on exertion or at rest, pleuritic chest pain, or dry cough promptly with a chest x-ray or additional diagnostic imaging as appropriate. Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. Severe pleural effusion may require thoracentesis and oxygen therapy. Consider dose reduction or treatment interruption <em>[see Posology and method of administration</em><strong> </strong><em>(4.2)].</em><strong> </strong>Patients aged 65 years and older are more likely than younger patients to experience pleural effusion, dyspnea, cough, pericardial effusion and congestive heart failure, and should be monitored closely. Cases of chylothorax have also been reported in patients presenting with pleural effusion <em>(see section 4.8</em>).</p><p>Cardiovascular Toxicity</p><p>SPRYCEL can cause cardiac dysfunction <em>[see Undesirable effects (4.8)].</em> After 5 years of follow-up in the randomized newly diagnosed chronic phase CML trial in adults (n=258), the following cardiac adverse reactions occurred: cardiac ischemic events (3.9% dasatinib vs 1.6% imatinib), cardiac-related fluid retention (8.5% dasatinib vs 3.9% imatinib), and conduction system abnormalities, most commonly arrhythmia and palpitations (7.0% dasatinib vs 5.0% imatinib). Two cases (0.8%) of peripheral arterial occlusive disease occurred with imatinib and 2 (0.8%) transient ischemic attacks occurred with dasatinib. Monitor patients for signs or symptoms consistent with cardiac dysfunction and treat appropriately.</p><p>Pulmonary Arterial Hypertension</p><p>SPRYCEL may increase the risk of developing pulmonary arterial hypertension (PAH) in adult and pediatric patients which may occur any time after initiation, including after more than 1 year of treatment. Manifestations include dyspnea, fatigue, hypoxia, and fluid retention <em>[see Undesirable effects (4.8)].</em> PAH may be reversible on discontinuation of SPRYCEL. Evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to initiating SPRYCEL and during treatment. If PAH is confirmed, SPRYCEL should be permanently discontinued.</p><p>QT Prolongation</p><p>SPRYCEL may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy <em>[see Undesirable effects (4.8)].</em> Correct hypokalemia or hypomagnesemia prior to and during SPRYCEL administration.</p><p>Severe Dermatologic Reactions</p><p>Cases of severe mucocutaneous dermatologic reactions, including Stevens-Johnson syndrome <em>[see Undesirable effects (4.8)]</em> and erythema multiforme, have been reported in patients treated with SPRYCEL. Discontinue permanently in patients who experience a severe mucocutaneous reaction during treatment if no other etiology can be identified.</p><p>Tumor Lysis Syndrome</p><p>Tumor lysis syndrome has been reported in patients with resistance to prior imatinib therapy, primarily in advanced phase disease. Due to potential for tumor lysis syndrome, maintain adequate hydration, correct uric acid levels prior to initiating therapy with SPRYCEL, and monitor electrolyte levels. Patients with advanced stage disease and/or high tumor burden may be at increased risk and should be monitored more frequently <em>[see Undesirable effects (4.8)].</em></p><p>Embryo-Fetal Toxicity</p><p>Based on limited human data, SPRYCEL can cause fetal harm when administered to a pregnant woman. Adverse pharmacologic effects of SPRYCEL including hydrops fetalis, fetal leukopenia, and fetal thrombocytopenia have been reported with maternal exposure to SPRYCEL. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with SPRYCEL and for 30 days after the last dose <em>[see Fertility, pregnancy and lactation (4.6)]</em>.</p><p>Effects on Growth and Development in Pediatric Patients</p><p>In pediatric trials of SPRYCEL in chronic phase CML after at least 2 years of treatment, adverse reactions associated with bone growth and development were reported in 5 (5.2%) patients, one of which was severe in intensity (Growth Retardation Grade 3). These 5 cases included cases of epiphyses delayed fusion, osteopenia, growth retardation, and gynecomastia <em>[see Undesirable effects (4.8)]</em>. Of these 5 cases, 1 case of osteopenia and 1 case of gynecomastia resolved during treatment.</p><p>Monitor bone growth and development in pediatric patients.</p><p>Hepatotoxicity</p><p>SPRYCEL may cause hepatotoxicity as measured by elevations in bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase. Monitor transaminases at baseline and monthly or as clinically indicated during treatment. Reduce dose, withhold, or permanently discontinue SPRYCEL based on severity. When SPRYCEL is administered in combination with chemotherapy, liver toxicity in the form of transaminase elevation and hyperbilirubinemia has been observed. Monitor hepatic function when SPRYCEL is used in combination with chemotherapy.</p><p>Hepatitis B virus reactivation</p><p>Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL tyrosine kinase inhibitors. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome.</p><p>Patients should be tested for HBV infection before initiating treatment with SPRYCEL. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with SPRYCEL should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy <em>[see Undesirable effects (4.8)]</em>.</p><p>Lactose</p><p>This medicinal product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of Other Drugs on Dasatinib</p><p>Strong CYP3A4 Inhibitors</p><p>The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations <em>[see Pharmacokinetic properties (5.2)]</em>. Increased dasatinib concentrations may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors. If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a SPRYCEL dose reduction <em>[see Posology and method of administration (4.2)]</em>.</p><p>Strong CYP3A4 Inducers</p><p>The coadministration of SPRYCEL with strong CYP3A inducers may decrease dasatinib concentrations <em>[see Pharmacokinetic properties (5.2)]</em>. Decreased dasatinib concentrations may reduce efficacy. Consider alternative drugs with less enzyme induction potential. If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a SPRYCEL dose increase.</p><p>Gastric Acid Reducing Agents</p><p>The coadministration of SPRYCEL with a gastric acid reducing agent may decrease the concentrations of dasatinib. Decreased dasatinib concentrations may reduce efficacy.</p><p>Do not administer H<sub>2</sub> antagonists or proton pump inhibitors with SPRYCEL. Consider the use of antacids in place of H<sub>2</sub> antagonists or proton pump inhibitors. Administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. Avoid simultaneous administration of SPRYCEL with antacids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>Pregnancy Category D</p><p>Risk Summary</p><p>Based on limited human data, SPRYCEL can cause fetal harm when administered to a pregnant woman. Adverse pharmacologic effects including hydrops fetalis, fetal leukopenia and fetal thrombocytopenia have been reported with maternal exposure to SPRYCEL. Animal reproduction studies in rats have demonstrated extensive mortality during organogenesis, the fetal period, and in neonates. Skeletal malformations were observed in a limited number of surviving rat and rabbit conceptuses. These findings occurred at dasatinib plasma concentrations below those in humans receiving therapeutic doses of dasatinib <em>[see Data]</em>. Advise a pregnant woman of the potential risk to a fetus.</p><p>The estimated background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.</p><p>Clinical Considerations</p><p>Fetal/Neonatal Adverse Reactions</p><p>Transplacental transfer of dasatinib has been reported. Dasatinib has been measured in fetal plasma and amniotic fluid at concentrations comparable to those in maternal plasma. Hydrops fetalis, fetal leukopenia and fetal thrombocytopenia have been reported with maternal exposure to dasatinib. These adverse pharmacologic effects on the fetus are similar to adverse reactions observed in adult patients and may result in fetal harm or neonatal death <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>Data</p><p>Human Data</p><p>Based on human experience, dasatinib is suspected to cause congenital malformations, including neural tube defects, and harmful pharmacological effects on the fetus when administered during pregnancy.</p><p>Animal Data</p><p>In nonclinical studies, at plasma concentrations below those observed in humans receiving therapeutic doses of dasatinib, embryo-fetal toxicities were observed in rats and rabbits. Fetal death was observed in rats. In both rats and rabbits, the lowest doses of dasatinib tested (rat: 2.5&nbsp;mg/kg/day [15 mg/m<sup>2</sup>/day] and rabbit: 0.5 mg/kg/day [6&nbsp;mg/m<sup>2</sup>/day]) resulted in embryo-fetal toxicities. These doses produced maternal AUCs of 105 ng&bull;h/mL and 44 ng&bull;h/mL (0.1-fold the human AUC) in rats and rabbits, respectively. Embryo-fetal toxicities included skeletal malformations at multiple sites (scapula, humerus, femur, radius, ribs, and clavicle), reduced ossification (sternum; thoracic, lumbar, and sacral vertebrae; forepaw phalanges; pelvis; and hyoid body), edema, and microhepatia. In a pre- and postnatal development study in rats, administration of dasatinib from gestation day (GD) 16 through lactation day (LD) 20, GD 21 through LD 20, or LD 4 through LD 20 resulted in extensive pup mortality at maternal exposures that were below the exposures in patients treated with dasatinib at the recommended labeling dose.</p><p>Lactation</p><p>Risk Summary</p><p>No data are available regarding the presence of dasatinib in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. However, dasatinib is present in the milk of lactating rats. Because of the potential for serious adverse reactions in nursing children from SPRYCEL, breastfeeding is not recommended during treatment with SPRYCEL and for 2 weeks after the last dose.</p><p>Females and Males of Reproductive Potential</p><p>SPRYCEL can cause fetal harm when administered to a pregnant woman <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>Contraception</p><p>Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with SPRYCEL and for 30 days after the last dose.</p><p>Infertility</p><p>Based on animal data, dasatinib may result in damage to female and male reproductive tissues<em> [see Special precautions for disposal and other handling (6.6)].</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SPRYCEL has minor influence on the ability to drive and use machines. Patients should be advised that they may experience adverse reactions such as dizziness or blurred vision during treatment with dasatinib. Therefore, caution should be recommended when driving a car or operating machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions</p><p>The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:</p><p>Myelosuppression <em>[see Posology and method of administration (4.2) and Special warnings and precautions for use (4.4)].</em></p><p>Bleeding-related events <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Fluid retention <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Cardiovascular toxicity <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Pulmonary arterial hypertension <em>[see Special warnings and precautions for use (4.4)].</em></p><p>QT prolongation <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Severe dermatologic reactions <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Tumor lysis syndrome <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Effects on growth and development in pediatric patients <em>[see Special warnings and precautions for use (4.4)].</em></p><p>&nbsp;</p><p>Summary of the safety profile</p><p>Clinical Trials Experience</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>The data described below reflect exposure to SPRYCEL administered as single-agent therapy at all doses tested in clinical studies (n=2809), including 324 adult patients with newly diagnosed chronic phase CML, 2388 adult patients with imatinib-resistant or -intolerant chronic or advanced phase CML or Ph+ ALL, and 97 pediatric patients with chronic phase CML. The median duration of therapy in a total of 2712 adult patients was 19.2 months (range 0 to 93.2 months). In a randomized trial in patients with newly diagnosed chronic phase CML, the median duration of therapy was approximately 60 months. The median duration of therapy in 1618 adult patients with chronic phase CML was 29 months (range 0 to 92.9 months).</p><p>The median duration of therapy in 1094 adult patients with advanced phase CML or Ph+ ALL was 6.2 months (range 0 to 93.2 months).</p><p>In two non-randomized trials in 97 pediatric patients with chronic phase CML (51 patients newly diagnosed and 46 patients resistant or intolerant to previous treatment with imatinib), the median duration of therapy was 51.1 months (range 1.9 to 99.6 months).</p><p>In the overall population of 2712 adult patients, 88% of patients experienced adverse reactions at some time and 19% experienced adverse reactions leading to treatment discontinuation.</p><p>In the randomized trial in adult patients with newly diagnosed chronic phase CML, drug was discontinued for adverse reactions in 16% of patients with a minimum of 60 months of follow-up. After a minimum of 60 months of follow-up, the cumulative discontinuation rate was 39%. Among the 1618 patients with chronic phase CML, drug-related adverse reactions leading to discontinuation were reported in 329 (20.3%) patients; among the 1094 patients with advanced phase CML or Ph+ ALL, drug-related adverse reactions leading to discontinuation were reported in 191 (17.5%) patients.</p><p>Among the 97 pediatric subjects, drug-related adverse reactions leading to discontinuation were reported in 1 patient (1%).</p><p>Adverse reactions reported in &ge;10% of adult patients, and other adverse reactions of interest, in a randomized trial in patients with newly diagnosed chronic phase CML at a median follow-up of approximately 60 months are presented in Table 6.</p><p>Adverse reactions reported in &ge;10% of adult patients treated at the recommended dose of 100 mg once daily (n=165), and other adverse reactions of interest, in a randomized dose-optimization trial of patients with chronic phase CML resistant or intolerant to prior imatinib therapy at a median follow-up of approximately 84 months are presented in Table 8.</p><p>Adverse reactions reported in &ge;10% of pediatric patients at a median follow-up of approximately 51.1 months are presented in Table 11.</p><p>Drug-related serious adverse reactions (SARs) were reported for 16.7% of adult patients in the randomized trial of patients with newly diagnosed chronic phase CML. Serious adverse reactions reported in &ge;5% of patients included pleural effusion (5%).</p><p>Drug-related SARs were reported for 26.1% of patients treated at the recommended dose of 100 mg once daily in the randomized dose-optimization trial of adult patients with chronic phase CML resistant or intolerant to prior imatinib therapy. Serious adverse reactions reported in &ge;5% of patients included pleural effusion (10%).</p><p>Drug-related SARs were reported for 14.4% of pediatric patients.</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p>Chronic Myeloid Leukemia (CML)</p><p>Adverse reactions (excluding laboratory abnormalities) that were reported in at least 10% of adult patients are shown in Table 6 for newly diagnosed patients with chronic phase CML and Tables 8 and 10 for CML patients with resistance or intolerance to prior imatinib therapy.</p><table border="0" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td colspan="5" style="vertical-align:top"><p>Table 6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Reported in &ge;10% of Adult Patients with Newly Diagnosed Chronic Phase CML (minimum of 60 months follow-up)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>All Grades</p></td><td colspan="2" style="vertical-align:top"><p>Grade 3/4</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Adverse Reaction</p></td><td style="vertical-align:top"><p>SPRYCEL<br />(n=258)</p></td><td style="vertical-align:top"><p>Imatinib<br />(n=258)</p></td><td style="vertical-align:top"><p>SPRYCEL<br />(n=258)</p></td><td style="vertical-align:top"><p>Imatinib<br />(n=258)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Percent (%) of Patients</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Fluid retention</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pleural effusion</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Superficial localized edema</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pulmonary hypertension</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Generalized edema</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pericardial effusion</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Congestive heart failure/<br />cardiac dysfunctiona</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pulmonary edema</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Rashb</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhagec</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Gastrointestinal bleeding</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Other bleedingd</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; CNS bleeding</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr></tbody></table><p>a&nbsp;&nbsp; Includes cardiac failure acute, cardiac failure congestive, cardiomyopathy, diastolic dysfunction, ejection fraction decreased, and left ventricular dysfunction.</p><p>b&nbsp;&nbsp; Includes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin exfoliation, and rash vesicular.</p><p>c&nbsp;&nbsp; Adverse reaction of special interest with &lt;10% frequency.</p><p>d&nbsp;&nbsp; Includes conjunctival hemorrhage, ear hemorrhage, ecchymosis, epistaxis, eye hemorrhage, gingival bleeding, hematoma, hematuria, hemoptysis, intra-abdominal hematoma, petechiae, scleral hemorrhage, uterine hemorrhage, and vaginal hemorrhage.</p><p>A comparison of cumulative rates of adverse reactions reported in &ge;10% of patients with minimum follow-up of 1 and 5 years in a randomized trial of newly diagnosed patients with chronic phase CML treated with SPRYCEL are shown in Table 7.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="5" style="vertical-align:top"><p>Table 7: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Reported in &ge;10% of Adult Patients with Newly Diagnosed Chronic Phase CML in the SPRYCEL-Treated Arm (n=258)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>Minimum of 1 Year Follow-up</p></td><td colspan="2" style="vertical-align:bottom"><p>Minimum of 5 Years Follow-up</p></td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p>Adverse Reaction</p></td><td style="vertical-align:top"><p>All Grades</p></td><td><p>Grade 3/4</p></td><td><p>All Grades</p></td><td><p>Grade 3/4</p></td></tr><tr><td colspan="4"><p>Percent (%) of Patients</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Fluid Retention</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pleural effusion</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Superficial localized edema</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pulmonary hypertension</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Generalized edema</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pericardial effusion</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Congestive heart failure/cardiac<br />dysfunction<sup>a</sup></p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pulmonary edema</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>b</sup></p></td><td style="vertical-align:bottom"><p>11</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:bottom"><p>14</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p><sup>a </sup>Includes cardiac failure acute, cardiac failure congestive, cardiomyopathy, diastolic dysfunction, ejection fraction decreased, and left ventricular dysfunction.</p><p><sup>b</sup>Includes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin exfoliation, and rash vesicular.</p><p>At 60 months, there were 26 deaths in dasatinib-treated patients (10.1%) and 26 deaths in imatinib-treated patients (10.1%); 1 death in each group was assessed by the investigator as related to study therapy.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Reported in &ge;10% of Adult Patients with Chronic Phase CML Resistant or Intolerant to Prior Imatinib Therapy (minimum of 84 months follow-up)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>100 mg Once Daily</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Chronic (n=165)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3/4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Percent (%) of Patients</strong></p></td></tr></thead><tbody><tr><td><p>Fluid retention</p></td><td><p>48</p></td><td><p>7</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Superficial localized edema</p></td><td><p>22</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Pleural effusion</p></td><td><p>28</p></td><td><p>5</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Generalized edema</p></td><td><p>4</p></td><td><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Pericardial effusion</p></td><td><p>3</p></td><td><p>1</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Pulmonary hypertension</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>Headache</p></td><td><p>33</p></td><td><p>1</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>28</p></td><td><p>2</p></td></tr><tr><td><p>Fatigue</p></td><td><p>26</p></td><td><p>4</p></td></tr><tr><td><p>Dyspnea</p></td><td><p>24</p></td><td><p>2</p></td></tr><tr><td><p>Musculoskeletal pain</p></td><td><p>22</p></td><td><p>2</p></td></tr><tr><td><p>Nausea</p></td><td><p>18</p></td><td><p>1</p></td></tr><tr><td><p>Skin rasha</p></td><td><p>18</p></td><td><p>2</p></td></tr><tr><td><p>Myalgia</p></td><td><p>13</p></td><td><p>0</p></td></tr><tr><td><p>Arthralgia</p></td><td><p>13</p></td><td><p>1</p></td></tr><tr><td><p>Infection (including bacterial, viral, fungal, and non-specified)</p></td><td><p>13</p></td><td><p>1</p></td></tr><tr><td><p>Abdominal pain</p></td><td><p>12</p></td><td><p>1</p></td></tr><tr><td><p>Hemorrhage</p></td><td><p>12</p></td><td><p>1</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Gastrointestinal bleeding</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>Pruritus</p></td><td><p>12</p></td><td><p>1</p></td></tr><tr><td><p>Pain</p></td><td><p>11</p></td><td><p>1</p></td></tr><tr><td><p>Constipation</p></td><td><p>10</p></td><td><p>1</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp; Includes drug eruption, erythema, erythema multiforme, erythrosis, exfoliative rash, generalized erythema, genital rash, heat rash, milia, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, skin exfoliation, skin irritation, urticaria vesiculosa, and rash vesicular.</p><p>&nbsp;</p><p>Cumulative rates of selected adverse reactions that were reported over time in patients treated with the 100 mg once daily recommended starting dose in a randomized dose-optimization trial of imatinib-resistant or<br />-intolerant patients with chronic phase CML are shown in Table 9.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:665px"><thead><tr><td><p>&nbsp;</p></td><td colspan="7" style="vertical-align:top"><p>Table 9:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Selected Adverse Reactions Reported in Adult Dose Optimization Trial (Imatinib-Intolerant or -Resistant Chronic Phase CML)a</p></td></tr><tr><td colspan="2"><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>Minimum of 2 Years Follow-up</strong></p></td><td colspan="2"><p><strong>Minimum of 5 Years Follow-up</strong></p></td><td colspan="2"><p><strong>Minimum of 7 Years Follow-up</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>All Grades</strong></p></td><td><p><strong>Grade 3/4</strong></p></td><td><p><strong>All Grades</strong></p></td><td><p><strong>Grade 3/4</strong></p></td><td><p><strong>All Grades</strong></p></td><td><p><strong>Grade 3/4</strong></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>Percent (%) of Patients</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Fluid retention</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Superficial edema</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pleural effusion</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Generalized edema</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pericardial effusion</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Pulmonary hypertension</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hemorrhage</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Gastrointestinal &nbsp;&nbsp;&nbsp; bleeding</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>a&nbsp;&nbsp; Randomized dose-optimization trial results reported in the recommended starting dose of 100 mg once daily (n=165) population.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="11" style="vertical-align:top"><p>Table 10:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Reported in &ge;10% of Adult Patients with Advanced Phase CML Resistant or Intolerant to Prior Imatinib Therapy</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="10" style="vertical-align:bottom"><p>140 mg Once Daily</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:bottom"><p>Accelerated<br />(n=157)</p></td><td colspan="4" style="vertical-align:bottom"><p>Myeloid Blast<br />(n=74)</p></td><td colspan="3" style="vertical-align:bottom"><p>Lymphoid Blast<br />(n=33)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>All<br />Grades</p></td><td colspan="2" style="vertical-align:top"><p>Grade<br />3/4</p></td><td colspan="2" style="vertical-align:top"><p>All</p><p>Grades</p></td><td colspan="2" style="vertical-align:top"><p>Grade 3/4</p></td><td colspan="2" style="vertical-align:top"><p>All Grades</p></td><td style="vertical-align:top"><p>Grade</p><p>3/4</p></td></tr><tr><td><p><strong>Adverse Reaction</strong></p></td><td colspan="10" style="vertical-align:top"><p>Percent (%) of Patients</p></td></tr></thead><tbody><tr><td><p>Fluid retention</p></td><td colspan="2"><p>35</p></td><td><p>8</p></td><td><p>34</p></td><td colspan="2"><p>7</p></td><td colspan="2"><p>21</p></td><td colspan="2"><p>6</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Superficial localized edema</p></td><td colspan="2"><p>18</p></td><td><p>1</p></td><td><p>14</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>3</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Pleural effusion</p></td><td colspan="2"><p>21</p></td><td><p>7</p></td><td><p>20</p></td><td colspan="2"><p>7</p></td><td colspan="2"><p>21</p></td><td colspan="2"><p>6</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Generalized edema</p></td><td colspan="2"><p>1</p></td><td><p>0</p></td><td><p>3</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Pericardial effusion</p></td><td colspan="2"><p>3</p></td><td><p>1</p></td><td><p>0</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Congestive heart failure/cardiac dysfunction<!--[if supportFields]><span
  style='mso-bookmark:Table_MISC2_2'></span><span style='mso-element:field-begin'></span><span
  style='mso-bookmark:Table_MISC2_2'><span class=BMSTableNote><span
  style='mso-ansi-font-size:10.0pt'> SEQ Table_MISC2 \* alphabetic \*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span></span><![endif]-->a<!--[if supportFields]><span
  style='mso-bookmark:Table_MISC2_2'></span><span style='mso-element:field-end'></span><![endif]--></p></td><td colspan="2"><p>0</p></td><td><p>0</p></td><td><p>4</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Pulmonary edema</p></td><td colspan="2"><p>1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td></tr><tr><td><p>Headache</p></td><td colspan="2"><p>27</p></td><td><p>1</p></td><td><p>18</p></td><td colspan="2"><p>1</p></td><td colspan="2"><p>15</p></td><td colspan="2"><p>3</p></td></tr><tr><td><p>Diarrhea</p></td><td colspan="2"><p>31</p></td><td><p>3</p></td><td><p>20</p></td><td colspan="2"><p>5</p></td><td colspan="2"><p>18</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>Fatigue</p></td><td colspan="2"><p>19</p></td><td><p>2</p></td><td><p>20</p></td><td colspan="2"><p>1</p></td><td colspan="2"><p>9</p></td><td colspan="2"><p>3</p></td></tr><tr><td><p>Dyspnea</p></td><td colspan="2"><p>20</p></td><td><p>3</p></td><td><p>15</p></td><td colspan="2"><p>3</p></td><td colspan="2"><p>3</p></td><td colspan="2"><p>3</p></td></tr><tr><td><p>Musculoskeletal pain</p></td><td colspan="2"><p>11</p></td><td><p>0</p></td><td><p>8</p></td><td colspan="2"><p>1</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>Nausea</p></td><td colspan="2"><p>19</p></td><td><p>1</p></td><td><p>23</p></td><td colspan="2"><p>1</p></td><td colspan="2"><p>21</p></td><td colspan="2"><p>3</p></td></tr><tr><td><p>Skin rash<!--[if supportFields]><span style='mso-bookmark:
  Table_MISC2_3'></span><span style='mso-element:field-begin'></span><span
  style='mso-bookmark:Table_MISC2_3'><span class=BMSTableNote><span
  style='mso-ansi-font-size:10.0pt'> SEQ Table_MISC2 \* alphabetic \*
  MERGEFORMAT <span style='mso-element:field-separator'></span></span></span></span><![endif]-->b<!--[if supportFields]><span
  style='mso-bookmark:Table_MISC2_3'></span><span style='mso-element:field-end'></span><![endif]--></p></td><td colspan="2"><p>15</p></td><td><p>0</p></td><td><p>16</p></td><td colspan="2"><p>1</p></td><td colspan="2"><p>21</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>Arthralgia</p></td><td colspan="2"><p>10</p></td><td><p>0</p></td><td><p>5</p></td><td colspan="2"><p>1</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>Infection (including bacterial, viral, fungal, and non-specified)</p></td><td colspan="2"><p>10</p></td><td><p>6</p></td><td><p>14</p></td><td colspan="2"><p>7</p></td><td colspan="2"><p>9</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>Hemorrhage</p></td><td colspan="2"><p>26</p></td><td><p>8</p></td><td><p>19</p></td><td colspan="2"><p>9</p></td><td colspan="2"><p>24</p></td><td colspan="2"><p>9</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Gastrointestinal bleeding</p></td><td colspan="2"><p>8</p></td><td><p>6</p></td><td><p>9</p></td><td colspan="2"><p>7</p></td><td colspan="2"><p>9</p></td><td colspan="2"><p>3</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; CNS bleeding</p></td><td colspan="2"><p>1</p></td><td><p>1</p></td><td><p>0</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>3</p></td><td colspan="2"><p>3</p></td></tr><tr><td><p>Vomiting</p></td><td colspan="2"><p>11</p></td><td><p>1</p></td><td><p>12</p></td><td colspan="2"><p>0</p></td><td colspan="2"><p>15</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>Pyrexia</p></td><td colspan="2"><p>11</p></td><td><p>2</p></td><td><p>18</p></td><td colspan="2"><p>3</p></td><td colspan="2"><p>6</p></td><td colspan="2"><p>0</p></td></tr><tr><td><p>Febrile neutropenia</p></td><td colspan="2"><p>4</p></td><td><p>4</p></td><td><p>12</p></td><td colspan="2"><p>12</p></td><td colspan="2"><p>12</p></td><td colspan="2"><p>12</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if supportFields]><sup><span
style='font-size:10.0pt;line-height:125%'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>SEQ Table_MISC2 Table_MISC2_2 \* alphabetic \*
MERGEFORMAT </span></sup><span style='font-size:10.0pt;line-height:125%'><span
style='mso-element:field-separator'></span></span><![endif]-->a<!--[if supportFields]><span
style='font-size:10.0pt;line-height:125%'><span style='mso-element:field-end'></span></span><![endif]-->&nbsp;&nbsp; Includes ventricular dysfunction, cardiac failure, cardiac failure congestive, cardiomyopathy, congestive cardio&shy;myopathy, diastolic dysfunction, ejection fraction decreased, and ventricular failure.</p><p><!--[if supportFields]><span style='mso-element:field-begin'></span><span
style='color:windowtext'><span style='mso-spacerun:yes'> </span>SEQ Table_MISC2
Table_MISC2_3 \* alphabetic \* MERGEFORMAT </span><span style='mso-element:
field-separator'></span><![endif]-->b<!--[if supportFields]><span
class=BMSTableNote><span style='mso-ansi-font-size:10.0pt;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></span><![endif]-->&nbsp;&nbsp; Includes drug eruption, erythema, erythema multiforme, erythrosis, exfoliative rash, generalized erythema, genital rash, heat rash, milia, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic, rash pustular, skin exfoliation, skin irritation, urticaria vesiculosa, and rash vesicular.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 11: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Reported in &sup3;10% of Dasatinib-Treated Pediatric Patients with Chronic Phase CML (n=97)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3/4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Percent (%) of Patients</strong></p></td></tr></thead><tbody><tr><td><p>Headache</p></td><td><p>28</p></td><td><p>3</p></td></tr><tr><td><p>Nausea</p></td><td><p>20</p></td><td><p>0</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>21</p></td><td><p>0</p></td></tr><tr><td><p>Skin rash</p></td><td><p>19</p></td><td><p>0</p></td></tr><tr><td><p>Vomiting</p></td><td><p>13</p></td><td><p>0</p></td></tr><tr><td><p>Pain in extremity</p></td><td><p>19</p></td><td><p>1</p></td></tr><tr><td><p>Abdominal pain</p></td><td><p>16</p></td><td><p>0</p></td></tr><tr><td><p>Fatigue</p></td><td><p>10</p></td><td><p>0</p></td></tr><tr><td><p>Arthralgia</p></td><td><p>10</p></td><td><p>1</p></td></tr></tbody></table><p>Adverse reactions associated with bone growth and development were reported in 5 (5.2%) of pediatric patients with chronic phase CML <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Laboratory Abnormalities</p><p>Myelosuppression was commonly reported in all patient populations. The frequency of Grade 3 or 4 neutropenia, thrombocytopenia, and anemia was higher in patients with advanced phase CML than in chronic phase CML (Tables 12 and 13). Myelosuppression was reported in patients with normal baseline laboratory values as well as in patients with pre‑existing laboratory abnormalities.</p><p>In patients who experienced severe myelosuppression, recovery generally occurred following dose interruption or reduction; permanent discontinuation of treatment occurred in 2% of adult patients with newly diagnosed chronic phase CML and 5% of adult patients with resistance or intolerance to prior imatinib therapy <em>[see </em><em>Special warnings and precautions for use (4.4)]</em>.</p><p>Grade 3 or 4 elevations of transaminases or bilirubin and Grade 3 or 4 hypocalcemia, hypokalemia, and hypophosphatemia were reported in patients with all phases of CML but were reported with an increased frequency in patients with myeloid or lymphoid blast phase CML. Elevations in transaminases or bilirubin were usually managed with dose reduction or interruption.<strong> </strong>Patients developing Grade 3 or 4 hypocalcemia during SPRYCEL therapy often had recovery with oral calcium supplementation.</p><p>Laboratory abnormalities reported in adult patients with newly diagnosed chronic phase CML are shown in Table 12. There were no discontinuations of SPRYCEL therapy in this patient population due to biochemical laboratory parameters.</p><table border="0" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 12:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTC Grade 3/4 Laboratory Abnormalities in Adult Patients with Newly Diagnosed Chronic Phase CML (minimum of 60 months follow-up)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>SPRYCEL<br />(n=258)</p></td><td><p>Imatinib<br />(n=258)</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="2"><p>Percent (%) of Patients</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Hematology Parameters</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Neutropenia</p></td><td><p>29</p></td><td><p>24</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Thrombocytopenia</p></td><td><p>22</p></td><td><p>14</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Anemia</p></td><td><p>13</p></td><td><p>9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Biochemistry Parameters</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hypophosphatemia</p></td><td><p>7</p></td><td><p>31</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hypokalemia</p></td><td><p>0</p></td><td><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Hypocalcemia</p></td><td><p>4</p></td><td><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Elevated SGPT (ALT)</p></td><td><p>&lt;1</p></td><td><p>2</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Elevated SGOT (AST)</p></td><td><p>&lt;1</p></td><td><p>1</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Elevated Bilirubin</p></td><td><p>1</p></td><td><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Elevated Creatinine</p></td><td><p>1</p></td><td><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CTC grades: neutropenia (Grade 3 &ge;0.5&ndash;&lt;1.0 &times; 109/L, Grade 4 &lt;0.5 &times; 109/L); thrombocytopenia (Grade&nbsp;3 &ge;25&ndash;&lt;50 &times; 109/L, Grade 4 &lt;25 &times; 109/L); anemia (hemoglobin Grade 3 &ge;65&ndash;&lt;80 g/L, Grade 4 &lt;65 g/L); elevated creatinine (Grade&nbsp;3 &gt;3&ndash;6 &times; upper limit of normal range (ULN), Grade 4 &gt;6 &times; ULN); elevated bilirubin (Grade 3 &gt;3&ndash;10 &times; ULN, Grade 4 &gt;10 &times; ULN); elevated SGOT or SGPT (Grade 3 &gt;5&ndash;20 &times; ULN, Grade&nbsp;4 &gt;20 &times; ULN); hypocalcemia (Grade&nbsp;3 &lt;7.0&ndash;6.0 mg/dL, Grade 4 &lt;6.0 mg/dL); hypophosphatemia (Grade 3 &lt;2.0&ndash;1.0 mg/dL, Grade 4 &lt;1.0&nbsp;mg/dL); hypokalemia (Grade 3 &lt;3.0&ndash;2.5 mmol/L, Grade 4 &lt;2.5 mmol/L).</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Laboratory abnormalities reported in patients with CML resistant or intolerant to imatinib who received the recommended starting doses of SPRYCEL are shown by disease phase in Table 13.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="6" style="vertical-align:top"><p>Table 13:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTC Grade 3/4 Laboratory Abnormalities in Clinical Studies of CML in Adults: Resistance or Intolerance to Prior Imatinib Therapy</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Chronic Phase CML<br />100 mg Once Daily</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Advanced Phase CML<br />140 mg Once Daily</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><br /><br /><strong>(n=165)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Accelerated<br />&nbsp;Phase (n=157)</strong></p></td><td style="vertical-align:top"><p><strong>Myeloid Blast<br />Phase (n=74)</strong></p></td><td style="vertical-align:top"><p><strong>Lymphoid Blast Phase (n=33)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Percent (%) of Patients</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Hematology Parameters*</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia</p></td><td style="vertical-align:top"><p>36</p></td><td colspan="2" style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>77</p></td><td style="vertical-align:top"><p>79</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia</p></td><td style="vertical-align:top"><p>24</p></td><td colspan="2" style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>78</p></td><td style="vertical-align:top"><p>85</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anemia</p></td><td style="vertical-align:top"><p>13</p></td><td colspan="2" style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>74</p></td><td style="vertical-align:top"><p>52</p></td></tr><tr><td style="vertical-align:top"><p><strong>Biochemistry Parameters</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypophosphatemia</p></td><td style="vertical-align:top"><p>10</p></td><td colspan="2" style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypokalemia</p></td><td style="vertical-align:top"><p>2</p></td><td colspan="2" style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypocalcemia</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td colspan="2" style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated SGPT (ALT)</p></td><td style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated SGOT (AST)</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated Bilirubin</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated Creatinine</p></td><td style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>CTC grades: neutropenia (Grade 3 &sup3;0.5&ndash;&lt;1.0 &times; 109/L, Grade 4 &lt;0.5 &times; 109/L); thrombocytopenia (Grade&nbsp;3 &sup3;25&ndash;&lt;50 &times; 109/L, Grade 4 &lt;25 &times; 109/L); anemia (hemoglobin Grade 3 &sup3;65&ndash;&lt;80 g/L, Grade 4 &lt;65 g/L); elevated creatinine (Grade&nbsp;3 &gt;3&ndash;6 &times; upper limit of normal range (ULN), Grade 4 &gt;6 &times; ULN); elevated bilirubin (Grade 3 &gt;3&ndash;10 &times; ULN, Grade 4 &gt;10 &times; ULN); elevated SGOT or SGPT (Grade 3 &gt;5&ndash;20 &times; ULN, Grade&nbsp;4 &gt;20 &times; ULN); hypocalcemia (Grade&nbsp;3 &lt;7.0&ndash;6.0 mg/dL, Grade 4 &lt;6.0 mg/dL); hypophosphatemia (Grade 3 &lt;2.0&ndash;1.0 mg/dL, Grade 4 &lt;1.0&nbsp;mg/dL); hypokalemia (Grade 3 &lt;3.0&ndash;2.5 mmol/L, Grade 4 &lt;2.5 mmol/L).</p><p>* Hematology parameters for 100 mg once-daily dosing in chronic phase CML reflects 60-month minimum follow-up.</p><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Among adult patients with chronic phase CML with resistance or intolerance to prior imatinib therapy, cumulative Grade 3 or 4 cytopenias were similar at 2 and 5 years including: neutropenia (36% vs 36%), thrombocytopenia (23% vs 24%), and anemia (13% vs 13%).</p><p>In the pediatric studies in CML, the rates of laboratory abnormalities were consistent with the known profile for laboratory parameters in adults.</p><p>Description of selected adverse reactions</p><p>Fluid retention</p><p>Miscellaneous adverse reactions such as pleural effusion, ascites, pulmonary edema and pericardial effusion with or without superficial edema may be collectively described as &ldquo;fluid retention&rdquo;. In the newly diagnosed chronic phase CML study after a minimum of 60 months follow-up, dasatinib-related fluid retention adverse reactions included pleural effusion (28%), superficial edema (14%), pulmonary hypertension (5%), generalized edema (4%), and pericardial effusion (4%). Congestive heart failure/cardiac dysfunction and pulmonary edema were reported in &lt; 2% of patients.</p><p>The cumulative rate of dasatinib-related pleural effusion (all grades) over time was 10% at 12 months, 14% at 24 months, 19% at 36 months, 24% at 48 months and 28% at 60 months. A total of 46 dasatinib-treated patients had recurrent pleural effusions. Seventeen patients had 2 separate adverse reactions, 6 had 3 adverse reactions, 18 had 4 to 8 adverse reactions and 5 had &gt; 8 episodes of pleural effusions.</p><p>The median time to first dasatinib-related grade 1 or 2 pleural effusion was 114 weeks (range: 4 to 299 weeks). Less than 10% of patients with pleural effusion had severe (grade 3 or 4) dasatinib-related pleural effusions. The median time to first occurrence of grade &ge; 3 dasatinib-related pleural effusion was 175 weeks (range: 114 to 274 weeks). The median duration of dasatinib-related pleural effusion (all grades) was 283 days (~40 weeks).</p><p>Pleural effusion was usually reversible and managed by interrupting SPRYCEL treatment and using diuretics or other appropriate supportive care measures (<em>see sections 4.2 and 4.4</em>). Among dasatinib-treated patients with drug-related pleural effusion (n=73), 45 (62%) had dose interruptions and 30 (41%) had dose reductions. Additionally, 34 (47%) received diuretics, 23 (32%) received corticosteroids, and 20 (27%) received both corticosteroids and diuretics. Nine (12%) patients underwent therapeutic thoracentesis.</p><p>Six percent of dasatinib-treated patients discontinued treatment due to drug-related pleural effusion. Pleural effusion did not impair the ability of patients to obtain a response. Among the dasatinib-treated patients with pleural effusion, 96% achieved a cCCyR, 82% achieved a MMR, and 50% achieved a MR4.5 despite dose interruptions or dose adjustment.</p><p>See section 4.4 for further information on patients with chronic phase CML and advanced phase CML or Ph+ ALL.</p><p>Cases of chylothorax have been reported in patients presenting with pleural effusion. Some cases of chylothorax resolved upon dasatinib discontinuation, interruption, or dose reduction, but most cases also required additional treatment.</p><p>Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+&nbsp;ALL) in Adults</p><p>A total of 135 adult patients with Ph+&nbsp;ALL were treated with SPRYCEL in clinical studies. The median duration of treatment was 3 months (range 0.03&ndash;31 months). The safety profile of patients with Ph+&nbsp;ALL was similar to those with lymphoid blast phase CML. The most frequently reported adverse reactions included fluid retention events, such as pleural effusion (24%) and superficial edema (19%), and gastrointestinal disorders, such as diarrhea (31%), nausea (24%), and vomiting (16%). Hemorrhage (19%), pyrexia (17%), rash (16%), and dyspnea (16%) were also frequently reported. Serious adverse reactions reported in &ge;5% of patients included pleural effusion (11%), gastrointestinal bleeding (7%), febrile neutropenia (6%), and infection (5%).</p><p>Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in Pediatric Patients</p><p>The safety of SPRYCEL administered continuously in combination with multiagent chemotherapy was determined in a multicohort study of 81 pediatric patients with newly diagnosed Ph+ ALL <em>[see Pharmacodynamic properties (5.1)].</em> The median duration of therapy was 24 months (range 2 to 27 months).</p><p>Fatal adverse reactions occurred in 3 patients (4%), all of which were due to infections. Eight (10%) patients experienced adverse reactions leading to treatment discontinuation, including fungal sepsis, hepatotoxicity in the setting of graft versus host disease, thrombocytopenia, CMV infection, pneumonia, nausea, enteritis and drug hypersensitivity.</p><p>The most common serious adverse reactions (incidence &ge;10%) were pyrexia, febrile neutropenia, mucositis, diarrhea, sepsis, hypotension, infections (bacterial, viral and fungal), hypersensitivity, vomiting, renal insufficiency, abdominal pain, and musculoskeletal pain.</p><p>The incidence of common adverse reactions (incidence <u>&gt;</u>20%) on study are shown in Table 14:</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><thead><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 14:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions Reported in &ge;20% of Pediatric Patients with Ph+ ALL Treated with SPRYCEL in Combination with Chemotherapy CA180372 (N=81)</strong></p></td></tr></thead><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>Percent (%) of Patients</strong></p></td></tr><tr><td><p><strong>Adverse Reaction</strong></p></td><td><p><strong>All Grades</strong></p></td><td><p><strong>Grade 3/4</strong></p></td></tr><tr><td><p>Mucositis</p></td><td><p>93</p></td><td><p>60</p></td></tr><tr><td><p>Febrile neutropenia</p></td><td><p>86</p></td><td><p>86</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td><p>85</p></td><td><p>17</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td><p>84</p></td><td><p>31</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td><p>84</p></td><td><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td><p>83</p></td><td><p>17</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain</p></td><td><p>83</p></td><td><p>25</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td><p>78</p></td><td><p>17</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td><p>78</p></td><td><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td><p>77</p></td><td><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td><p>68</p></td><td><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td><p>59</p></td><td><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td><p>57</p></td><td><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia</p></td><td><p>47</p></td><td><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>47</p></td><td><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Edema</p></td><td style="vertical-align:top"><p>47</p></td><td><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Viral infection</p></td><td><p>40</p></td><td><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td><p>40</p></td><td><p>26</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td><p>38</p></td><td><p>22</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity</p></td><td><p>36</p></td><td><p>20</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td><p>36</p></td><td><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea</p></td><td><p>35</p></td><td><p>10</p></td></tr><tr><td><p>Epistaxis</p></td><td><p>31</p></td><td><p>6</p></td></tr><tr><td><p>Peripheral neuropathy</p></td><td><p>31</p></td><td><p>7</p></td></tr><tr><td><p>Sepsis (excluding fungal)</p></td><td><p>n/a</p></td><td><p>31</p></td></tr><tr><td><p>Altered state of consciousness</p></td><td><p>30</p></td><td><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Fungal infection</p></td><td><p>30</p></td><td><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia (excluding fungal)</p></td><td><p>28</p></td><td><p>25</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td><p>28</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Clostridial infection (excluding sepsis)</p></td><td><p>25</p></td><td><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Urinary Tract Infection</p></td><td><p>24</p></td><td><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Bacteremia (excluding fungal)</p></td><td><p>22</p></td><td><p>20</p></td></tr><tr><td><p>Erythema</p></td><td><p>22</p></td><td><p>6</p></td></tr><tr><td><p>Chills</p></td><td><p>21</p></td><td><p>-</p></td></tr><tr><td><p>Pleural effusion</p></td><td><p>21</p></td><td><p>9</p></td></tr><tr><td><p>Sinusitis</p></td><td><p>21</p></td><td><p>10</p></td></tr><tr><td><p>Dehydration</p></td><td><p>20</p></td><td><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td><p>20</p></td><td><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Visual impairment</p></td><td><p>20</p></td><td><p>-</p></td></tr></tbody></table><p>&nbsp;</p><p>The incidence of common adverse reactions attributed by the investigator to SPRYCEL (reported at a frequency of <strong>&ge;</strong>10%, all grades and grade 3/4, respectively) on study (N=81), included febrile neutropenia (23%, 23%), nausea (21%, 4%), vomiting (19%, 4%), mucositis (17%, 6%), musculoskeletal pain (17%, 2%), abdominal pain (16%, 5%), diarrhea (16%, 7%), rash (15%, 0%), fatigue (12%, 0%), pyrexia (12%, 6%), and headache (12%, 5%).</p><p>&nbsp;</p><p>CTCAE grade 3/4 laboratory abnormalities in pediatric patients with Ph+ ALL treated with SPRYCEL in combination with chemotherapy are shown in Table 15.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 15:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE Grade 3/4 Laboratory Abnormalities in &ge;10% of Pediatric Patients with Ph+ ALL Treated with SPRYCEL in Combination with Chemotherapy CA180372 (N=81)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Percent (%) of Patients</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Hematology Parameters</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia</p></td><td style="vertical-align:top"><p>96</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia</p></td><td style="vertical-align:top"><p>88</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anemia</p></td><td style="vertical-align:top"><p>82</p></td></tr><tr><td style="vertical-align:top"><p><strong>Biochemistry Parameters</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated SGPT (ALT)</p></td><td style="vertical-align:top"><p>47</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypokalemia</p></td><td style="vertical-align:top"><p>40</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated SGOT (AST)</p></td><td style="vertical-align:top"><p>26</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypocalcemia</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyponatremia</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated Bilirubin</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypophosphatemia</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Toxicity grading is per CTCAE version 4.</p></td></tr></tbody></table><p>Additional Pooled Data from Clinical Trials</p><p>The following additional adverse reactions were reported in adult and pediatric patients (n=2809) in SPRYCEL CML clinical studies and adult patients in Ph+ ALL clinical studies at a frequency of &ge;10%, 1%&ndash;&lt;10%, 0.1%&ndash;&lt;1%, or &lt;0.1%. These adverse reactions are included based on clinical relevance.</p><p><strong><em>Gastrointestinal Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>mucosal inflammation (including mucositis/stomatitis), dyspepsia, abdominal distension, constipation, gastritis, colitis (including neutropenic colitis), oral soft tissue disorder; <em>0.1%&ndash;&lt;1% &ndash; </em>ascites, dysphagia, anal fissure, upper gastrointestinal ulcer, esophagitis, pancreatitis, gastroesophageal reflux disease; <em>&lt;0.1% &ndash; </em>protein losing gastroenteropathy, ileus, acute pancreatitis, anal fistula.</p><p><strong><em>General Disorders and Administration Site</em></strong>-<strong><em>Conditions: </em></strong><em>&ge;10% </em>&ndash; peripheral edema, face edema; <em>1%&ndash;&lt;10% </em>&ndash; asthenia, chest pain, chills; <em>0.1%&ndash;&lt;1% &ndash; </em>malaise, other superficial edema, peripheral swelling; <em>&lt;0.1% </em>&ndash; gait disturbance.</p><p><strong><em>Skin and Subcutaneous Tissue Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>alopecia, acne, dry skin, hyperhidrosis, urticaria, dermatitis (including eczema); <em>0.1%&ndash;&lt;1% &ndash; </em>pigmentation disorder, skin ulcer, bullous conditions, photosensitivity, nail disorder, neutrophilic dermatosis, panniculitis, palmar-plantar erythrodysesthesia syndrome, hair disorder; <em>&lt;0.1% </em>&ndash; leukocytoclastic vasculitis, skin fibrosis.</p><p><strong><em>Respiratory, Thoracic, and Mediastinal Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>lung infiltration, pneumonitis, cough; <em>0.1%&ndash;&lt;1% &ndash; </em>asthma, bronchospasm, dysphonia, pulmonary arterial hypertension; chylothorax; <em>&lt;0.1% </em>&ndash; acute respiratory distress syndrome, pulmonary embolism.</p><p><strong><em>Nervous System Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>neuropathy (including peripheral neuropathy)<em>, </em>dizziness, dysgeusia, somnolence; <em>0.1%&ndash;&lt;1% &ndash; </em>amnesia, tremor, syncope, balance disorder; <em>&lt;0.1% </em>&ndash; convulsion, cerebrovascular accident, transient ischemic attack, optic neuritis, VIIth nerve paralysis, dementia, ataxia</p><p><strong><em>Blood and Lymphatic System Disorders:</em> </strong>0.1%&ndash;&lt;1% &ndash; lymphadenopathy, lymphopenia; &lt;0.1% &ndash; aplasia pure red cell.</p><p><strong><em>Musculoskeletal and Connective Tissue Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>muscular weakness, musculoskeletal stiffness; <em>0.1%&ndash;&lt;1% &ndash; </em>rhabdomyolysis, tendonitis, muscle inflammation, osteonecrosis, arthritis; <em>&lt;0.1% &ndash; </em>epiphyses delayed fusion (reported at <em>1%-&lt;10%</em> in the pediatric studies), growth retardation (reported at <em>1%-&lt;10%</em> in the pediatric studies).</p><p><strong><em>Investigations: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>weight increased, weight decreased; <em>0.1%&ndash;&lt;1% &ndash; </em>blood creatine phosphokinase increased, gamma-glutamyltransferase increased.</p><p><strong><em>Infections and Infestations:</em></strong> 1%&ndash;&lt;10% &ndash; pneumonia (including bacterial, viral, and fungal), upper respiratory tract infection/inflammation, herpes virus infection, enterocolitis infection, sepsis (including fatal outcomes [0.2%]).</p><p><strong><em>Metabolism and Nutrition Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>appetite disturbances, hyperuricemia; <em>0.1%&ndash;&lt;1% &ndash; </em>hypoalbuminemia, tumor lysis syndrome, dehydration, hypercholesterolemia; <em>&lt;0.1% &ndash; </em>diabetes mellitus.</p><p><strong><em>Cardiac Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>arrhythmia (including tachycardia), palpitations; <em>0.1%&ndash;&lt;1% &ndash; </em>angina pectoris, cardiomegaly, pericarditis, ventricular arrhythmia (including ventricular tachycardia), electrocardiogram T-wave abnormal, troponin increased; <em>&lt;0.1% &ndash; </em>cor pulmonale, myocarditis, acute coronary syndrome, cardiac arrest, electrocardiogram PR prolongation, coronary artery disease, pleuropericarditis.</p><p><strong><em>Eye Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>visual disorder (including visual disturbance, vision blurred, and visual acuity reduced), dry eye; <em>0.1%&ndash;&lt;1% </em>&ndash; conjunctivitis, visual impairment, lacrimation increased, <em>&lt;0.1% &ndash; -</em>photophobia.</p><p><strong><em>Vascular Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>flushing, hypertension; <em>0.1%&ndash;&lt;1% &ndash; </em>hypotension, thrombophlebitis, thrombosis; <em>&lt;0.1% </em>&ndash; livedo reticularis, deep vein thrombosis, embolism.</p><p><strong><em>Psychiatric Disorders: </em></strong><em>1%&ndash;&lt;10% &ndash; </em>insomnia, depression; <em>0.1%&ndash;&lt;1% &ndash; </em>anxiety, affect lability, confusional state, libido decreased.</p><p><strong><em>Pregnancy, Puerperium, and Perinatal Conditions:</em></strong> &lt;0.1% &ndash; abortion.</p><p><strong><em>Reproductive System and Breast Disorders:</em> </strong>0.1%&ndash;&lt;1% &ndash; gynecomastia, menstrual disorder.</p><p><strong><em>Injury, Poisoning, and Procedural Complications:</em></strong> 1%&ndash;&lt;10% &ndash; contusion.</p><p><strong><em>Ear and Labyrinth Disorders:</em> </strong>1%&ndash;&lt;10% &ndash; tinnitus; 0.1%&ndash;&lt;1% &ndash; vertigo, hearing loss.</p><p><strong><em>Hepatobiliary Disorders: </em></strong><em>0.1%&ndash;&lt;1% </em>&ndash; cholestasis, cholecystitis, hepatitis.</p><p><strong><em>Renal and Urinary Disorders: </em></strong><em>0.1%&ndash;&lt;1% </em>&ndash; urinary frequency, renal failure, proteinuria; <em>&lt;0.1% &ndash; </em>renal impairment.</p><p><strong><em>Immune System Disorders: </em></strong><em>0.1%&ndash;&lt;1% </em>&ndash; hypersensitivity (including erythema nodosum).</p><p><strong><em>Endocrine Disorders: </em></strong><em>0.1%&ndash;&lt;1% &ndash; </em>hypothyroidism; <em>&lt;0.1% &ndash; </em>hyperthyroidism, thyroiditis.</p><p>&nbsp;</p><p>Pediatric population</p><p>Pediatric Use</p><p>Ph+ CML in Chronic Phase</p><p>The safety and effectiveness of SPRYCEL monotherapy have been demonstrated in pediatric patients with newly diagnosed chronic phase CML <em>[see PHARMACOLOGICAL PROPERTIES (5)]</em>. There are no data in children under 1 year of age. Adverse reactions associated with bone growth and development were reported in 5 (5.2%) of patients <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>Ph+ ALL</p><p>The safety and effectiveness of SPRYCEL in combination with chemotherapy have been demonstrated in pediatric patients one year and over with newly diagnosed Ph+ ALL. Use of SPRYCEL in pediatric patients is supported by evidence from one pediatric study. There are no data in children under 1 year of age. One case of Grade 1 osteopenia was reported.</p><p>The safety profile of SPRYCEL in pediatric subjects was comparable to that reported in studies in adult subjects <em>[see Undesirable effects (4.8) and PHARMACOLOGICAL PROPERTIES (5)]</em>.</p><p>Monitor bone growth and development in pediatric patients <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>Pediatric Patients with Difficulty Swallowing Tablets</p><p>Five patients with Ph+ ALL 2 to 10 years of age received at least one dose of SPRYCEL tablet dispersed in juice on Study CA180372. The exposure for dispersed tablets was 36% lower as compared to intact tablets in pediatric patients <em>[see Interaction with other medicinal products and other forms of interaction (4.5)]</em>. Due to the limited available clinical data, it is unclear whether dispersing SPRYCEL tablets significantly alters the safety and/or efficacy of SPRYCEL.</p><p>Other special populations</p><p>Geriatric Use</p><p>Of the 2712 patients in clinical studies of SPRYCEL, 617 (23%) were 65 years of age and older, and 123 (5%) were 75 years of age and older. No differences in confirmed Complete Cytogenetic Response (cCCyR) and MMR were observed between older and younger patients. While the safety profile of SPRYCEL in the geriatric population was similar to that in the younger population, patients aged 65 years and older are more likely to experience the commonly reported adverse reactions of fatigue, pleural effusion, diarrhea, dyspnea, cough, lower gastrointestinal hemorrhage, and appetite disturbance, and more likely to experience the less frequently reported adverse reactions of abdominal distention, dizziness, pericardial effusion, congestive heart failure, hypertension, pulmonary edema, and weight decrease, and should be monitored closely. <em>(See Section 4.2, Posology and method of administration.)</em></p><p>4.8.3 Post-marketing Experience</p><p>The following additional adverse reactions have been identified during post approval use of SPRYCEL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p><strong>Infections: </strong>hepatitis B virus reactivation</p><p><strong>Cardiac disorders</strong><strong>: </strong>atrial fibrillation/atrial flutter</p><p><strong>Respiratory, thoracic, and mediastinal disorders:</strong> interstitial lung disease</p><p><strong>Skin and subcutaneous tissue disorders:</strong> Stevens-Johnson syndrome</p><p><strong>Renal and urinary disorders:</strong> nephrotic syndrome</p><p><strong>Blood and lymphatic system disorders:</strong> thrombotic microangiopathy</p><p>&nbsp;</p><p>&nbsp;</p><p>Please report adverse drug events to:</p><p>&nbsp;</p><p>Saudi Arabia</p><table border="0" cellspacing="0" cellpadding="0" style="width:462px"><tbody><tr><td style="vertical-align:top">&nbsp;<p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>Other GCC states</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:462px"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with overdose of SPRYCEL in clinical studies is limited to isolated cases. The highest overdosage of 280 mg per day for 1 week was reported in two patients and both developed severe myelosuppression and bleeding. Since SPRYCEL is associated with severe myelosuppression, <em>[see Special warnings and precautions for use (4.4) and</em> <em>Undesirable effects (4.8)]</em>, monitor patients who ingest more than the recommended dosage closely for myelosuppression and give appropriate supportive treatment.</p><p>Acute overdose in animals was associated with cardiotoxicity. Evidence of cardiotoxicity included ventricular necrosis and valvular/ventricular/atrial hemorrhage at single doses &sup3;100&nbsp;mg/kg (600 mg/m2) in rodents. There was a tendency for increased systolic and diastolic blood pressure in monkeys at single doses &sup3;10 mg/kg<br />(120 mg/m2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</p><p>SPRYCEL (dasatinib) is a kinase inhibitor <em>[see Pharmacokinetic properties (5.2)]</em>. ATC code: L01EA02</p><p>Mechanism of Action</p><p>Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR‑ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR&beta;. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.</p><p><em>In vitro</em>, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR‑ABL. Under the conditions of the assays, dasatinib could overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.</p><p>Pharmacodynamic effects</p><p>Cardiac Electrophysiology</p><p>Of 2440 patients treated with SPRYCEL at all doses tested in clinical trials, 16 patients (&lt;1%) had QTc prolongation reported as an adverse reaction. Twenty-two patients (1%) experienced a QTcF &gt;500 ms. In 865 patients with leukemia treated with SPRYCEL 70 mg BID in five Phase 2 studies, the maximum mean changes in QTcF (90% upper bound CI) from baseline ranged from 7 ms to 13.4 ms.</p><p>An analysis of the data from five Phase 2 studies in patients (70 mg BID) and a Phase 1 study in healthy subjects (100 mg single dose) suggests that there is a maximum increase of 3 to 6 milliseconds in Fridericia corrected QTc interval from baseline for subjects receiving therapeutic doses of dasatinib, with associated upper 95% confidence intervals &lt;10 msec.</p><p>Clinical efficacy and safety</p><p>Newly Diagnosed Chronic Phase CML in Adults</p><p>DASISION (Dasatinib vs Imatinib Study in Treatment-Na&iuml;ve Chronic Myeloid Leukemia Patients) was an open-label, multicenter, international, randomized trial conducted in adult patients with newly diagnosed chronic phase CML. A total of 519 patients were randomized to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily. Patients with a history of cardiac disease were included in this trial except those who had a myocardial infarction within 6&nbsp;months, congestive heart failure within 3&nbsp;months, significant arrhythmias, or QTc prolongation. The primary endpoint was the rate of confirmed complete cytogenetic response (CCyR) within 12&nbsp;months. Confirmed CCyR was defined as a CCyR noted on two consecutive occasions (at least 28 days apart).</p><p>Median age was 46 years in the SPRYCEL group and 49 years in the imatinib groups, with 10% and 11% of patients &sup3;65 years of age, respectively. There were slightly more male than female patients in both groups (59% vs 41%). Fifty-three percent of all patients were Caucasian and 39% were Asian.&nbsp;At baseline, the distribution of Hasford scores was similar in the SPRYCEL and imatinib treatment groups (low risk: 33% and 34%; intermediate risk: 48% and 47%; high risk: 19% and 19%, respectively). With a minimum of 12 months follow-up, 85% of patients randomized to SPRYCEL and 81% of patients randomized to imatinib were still on study.</p><p>With a minimum of 24 months follow-up, 77% of patients randomized to SPRYCEL and 75% of patients randomized to imatinib were still on study and with a minimum of 60 months follow-up, 61% and 62% of patients, respectively, were still on treatment at the time of study closure.</p><p>Efficacy results are summarized in Table 16.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="5" style="vertical-align:top"><p>Table 16:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy Results in a Randomized Newly Diagnosed Chronic Phase CML Trial</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>SPRYCEL<br />(n=259)</p></td><td style="vertical-align:top"><p>Imatinib<br />(n=260)</p></td><td><p><s>&nbsp;</s></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Confirmed CCyR</strong>a</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Within 12 months</strong> <strong>(95% CI) </strong></p></td><td><p>76.8% (71.2&ndash;81.8)</p></td><td><p>&nbsp; 66.2% (60.1&ndash;71.9)</p></td><td><p><s>&nbsp;</s></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P-value </strong></p></td><td><p><s>&nbsp;</s></p></td><td><p>0.007*</p></td><td><p><s>&nbsp;</s></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Major Molecular Response</strong>b</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>12 months </strong><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p>52.1% (45.9&ndash;58.3)</p></td><td style="vertical-align:top"><p>33.8% (28.1&ndash;39.9)</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P-value</strong></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60 months (95% CI)</strong></p></td><td style="vertical-align:top"><p>76.4% (70.8&ndash;81.5)</p></td><td style="vertical-align:top"><p>64.2% (58.1&ndash;70.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>a&nbsp;&nbsp; Confirmed CCyR is defined as a CCyR noted on two consecutive occasions at least 28 days apart.</p><p>b<strong><sup>&nbsp;&nbsp;&nbsp; </sup></strong>Major molecular response (at any time) was defined as BCR-ABL ratios &pound;0.1% by RQ-PCR in peripheral blood samples standardized on the International scale. These are cumulative rates representing minimum follow-up for the time frame specified.</p><p>*&nbsp;&nbsp; Adjusted for Hasford score and indicated statistical significance at a pre-defined nominal level of significance.</p><p>CI = confidence interval.</p><p>&nbsp;</p><p>The confirmed CCyR within 24, 36, and 60 months for SPRYCEL versus imatinib arms were 80% versus 74%, 83% versus 77%, and 83% versus 79%, respectively. The MMR at 24 and 36 months for SPRYCEL versus imatinib arms were 65% versus 50% and 69% versus 56%, respectively.</p><p>After 60 months follow-up, median time to confirmed CCyR was 3.1 months in 215 SPRYCEL responders and 5.8 months in 204 imatinib responders. Median time to MMR after 60 months follow-up was 9.3 months in 198 SPRYCEL responders and 15.0 months in 167 imatinib responders.</p><p>At 60 months, 8 patients (3%) on the dasatinib arm progressed to either accelerated phase or blast crisis while 15 patients (6%) on the imatinib arm progressed to either accelerated phase or blast crisis.</p><p>The estimated 60-month survival rates for SPRYCEL- and imatinib-treated patients were 90.9% (CI: 86.6%&ndash;93.8%) and 89.6% (CI: 85.2%&ndash;92.8%), respectively. Based on data 5 years after the last patient was enrolled in the trial, 83% and 77% of patients were known to be alive in the dasatinib and imatinib treatment groups, respectively, 10% were known to have died in both treatment groups, and 7% and 13% had unknown survival status in the dasatinib and imatinib treatment groups, respectively.</p><p>At 60 months follow-up in the SPRYCEL arm, the rate of MMR at any time in each risk group determined by Hasford score was 90% (low risk), 71% (intermediate risk) and 67% (high risk). In the imatinib arm, the rate of MMR at any time in each risk group determined by Hasford score was 69% (low risk), 65% (intermediate risk), and 54% (high risk).</p><p>BCR-ABL sequencing was performed on blood samples from patients in the newly diagnosed trial who discontinued dasatinib or imatinib therapy.&nbsp;Among dasatinib-treated patients the mutations detected were T315I, F317I/L, and V299L.</p><p>Dasatinib does not appear to be active against the T315I mutation, based on <em>in vitro</em> data.</p><p>Imatinib-Resistant or -Intolerant CML or Ph+ ALL in Adults</p><p>The efficacy and safety of SPRYCEL were investigated in adult patients with CML or Ph+&nbsp;ALL whose disease was resistant to or who were intolerant to imatinib: 1158&nbsp;patients had chronic phase CML, 858 patients had accelerated phase, myeloid blast phase, or lymphoid blast phase CML, and 130 patients had Ph+&nbsp;ALL. In a clinical trial in chronic phase CML, resistance to imatinib was defined as failure to achieve a complete hematologic response (CHR; after 3&nbsp;months), major cytogenetic response (MCyR; after 6&nbsp;months), or complete cytogenetic response (CCyR; after 12&nbsp;months); or loss of a previous molecular response (with concurrent &sup3;10% increase in Ph+ metaphases), cytogenetic response, or hematologic response. Imatinib intolerance was defined as inability to tolerate 400 mg or more of imatinib per day or discontinuation of imatinib because of toxicity.</p><p>Results described below are based on a minimum of 2 years follow-up after the start of SPRYCEL therapy in patients with a median time from initial diagnosis of approximately 5&nbsp;years. Across all studies, 48% of patients were women, 81% were white, 15% were black or Asian, 25% were 65 years of age or older, and 5% were 75 years of age or older. Most patients had long disease histories with extensive prior treatment, including imatinib, cytotoxic chemotherapy, interferon, and stem cell transplant. Overall, 80% of patients had imatinib-resistant disease and 20% of patients were intolerant to imatinib. The maximum imatinib dose had been 400&ndash;600 mg/day in about 60% of the patients and</p><p>&nbsp;&gt;600 mg/day in 40% of the patients.</p><p>The primary efficacy endpoint in chronic phase CML was MCyR, defined as elimination (CCyR) or substantial diminution (by at least 65%, partial cytogenetic response) of Ph+&nbsp;hematopoietic cells. The primary efficacy endpoint in accelerated phase, myeloid blast phase, lymphoid blast phase CML, and Ph+&nbsp;ALL was major hematologic response (MaHR), defined as either a CHR or no evidence of leukemia (NEL).</p><p>Chronic Phase CML</p><p><em>Dose-Optimization Trial: </em>A randomized, open-label trial was conducted in adult patients with chronic phase CML to evaluate the efficacy and safety of SPRYCEL administered once daily compared with SPRYCEL administered twice daily. Patients with significant cardiac diseases, including myocardial infarction within 6 months, congestive heart failure within 3&nbsp;months, significant arrhythmias, or QTc prolongation were excluded from the trial. The primary efficacy endpoint was MCyR in patients with imatinib-resistant CML. A total of 670&nbsp;patients, of whom 497 had imatinib-resistant disease, were randomized to the SPRYCEL 100 mg once-daily, 140 mg once-daily, 50 mg twice-daily, or 70 mg twice-daily group. Median duration of treatment was 22&nbsp;months.</p><p>Efficacy was achieved across all SPRYCEL treatment groups with the once-daily schedule demonstrating comparable efficacy (non-inferiority) to the twice-daily schedule on the primary efficacy endpoint (difference in MCyR 1.9%; 95% CI [&minus;6.8%&ndash;10.6%]); however, the 100-mg once-daily regimen demonstrated improved safety and tolerability.</p><p>Efficacy results are presented in Tables 17 and 18 for adult patients with chronic phase CML who received the recommended starting dose of 100 mg once daily.</p><table border="1" cellspacing="0" cellpadding="0" style="width:101%"><thead><tr><td colspan="2" style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Table 17</strong><strong>:</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Efficacy of SPRYCEL in Adult Patients with Imatinib-Resistant or -Intolerant&nbsp;<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chronic Phase CML (minimum of 24 months follow-up)</strong></p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td style="width:457px"><p>All Patients</p></td><td style="width:524px"><p><strong>100 mg Once Daily<br />(n=167)</strong></p></td></tr></thead><tbody><tr><td style="width:457px"><p><strong>Hematologic Response Rate % (95% CI) </strong></p><p>CHR<!--[if supportFields]><span
  style='mso-bookmark:Table_MISC3_2'><span style='mso-bookmark:_Toc147808627'></span></span><span
  style='mso-element:field-begin'></span><span style='mso-bookmark:Table_MISC3_2'><span
  style='mso-bookmark:_Toc147808627'><span class=BMSTableNote><span
  style='font-size:14.0pt;mso-bidi-font-size:10.0pt'> SEQ Table_MISC3 \*
  alphabetic \* MERGEFORMAT <span style='mso-element:field-separator'></span></span></span></span></span><![endif]-->a<!--[if supportFields]><span
  style='mso-bookmark:Table_MISC3_2'><span style='mso-bookmark:_Toc147808627'></span></span><span
  style='mso-element:field-end'></span><![endif]--></p></td><td style="width:524px"><p>&nbsp;</p><p>92% (86&ndash;95)</p></td></tr><tr><td style="width:457px"><p><strong>Cytogenetic Response Rate % (95% CI) </strong></p><p>MCyR<!--[if supportFields]><span style='mso-bookmark:
  Table_MISC3_3'><span style='mso-bookmark:_Toc147808627'></span></span><span
  style='mso-element:field-begin'></span><span style='mso-bookmark:Table_MISC3_3'><span
  style='mso-bookmark:_Toc147808627'><span class=BMSTableNote><span
  style='font-size:14.0pt;mso-bidi-font-size:10.0pt'> SEQ Table_MISC3 \*
  alphabetic \* MERGEFORMAT <span style='mso-element:field-separator'></span></span></span></span></span><![endif]-->b<!--[if supportFields]><span
  style='mso-bookmark:Table_MISC3_3'><span style='mso-bookmark:_Toc147808627'></span></span><span
  style='mso-element:field-end'></span><![endif]--></p></td><td style="width:524px"><p>&nbsp;</p><p>&nbsp;</p><p>63% (56&ndash;71)</p></td></tr><tr><td style="width:457px"><p>CCyR</p></td><td style="width:524px"><p>50% (42&ndash;58)</p></td></tr></tbody></table><p><!--[if supportFields]><span
style='mso-bookmark:_Toc147808627'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Toc147808627'><span style='color:windowtext'><span
style='mso-spacerun:yes'> </span>SEQ Table_MISC3 Table_MISC3_2 \* alphabetic \*
MERGEFORMAT </span><span style='mso-element:field-separator'></span></span><![endif]-->a<!--[if supportFields]><span
style='mso-bookmark:_Toc147808627'></span><span style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp;&nbsp; CHR (response confirmed after 4 weeks): WBC &pound; institutional ULN, platelets &lt;450,000/mm3, no blasts or promyelocytes in peripheral blood, &lt;5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt;20%, and no extramedullary involvement.</p><p><!--[if supportFields]><span
style='mso-bookmark:_Toc147808627'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Toc147808627'><span style='color:windowtext'><span
style='mso-spacerun:yes'> </span>SEQ Table_MISC3 Table_MISC3_3 \* alphabetic \*
MERGEFORMAT </span><span style='mso-element:field-separator'></span></span><![endif]-->b<!--[if supportFields]><span
style='mso-bookmark:_Toc147808627'></span><span style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp;&nbsp; MCyR combines both complete (0% Ph+ metaphases) and partial (&gt;0%&ndash;35%) responses.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:637px"><tbody><tr><td colspan="6"><p>Table 18:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-Term MMR of SPRYCEL in the Dose Optimization Trial: Adult Patients with Imatinib-Resistant or -Intolerant Chronic Phase CMLa</p></td></tr></tbody><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p>Minimum Follow-up Period</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2 Years</p></td><td style="vertical-align:top"><p>5 Years</p></td><td style="vertical-align:top"><p>7 Years</p></td></tr></thead><tbody><tr><td colspan="6"><p><strong>Major Molecular Response</strong><strong>b </strong><strong>% (n/N)</strong></p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; All Patients Randomized</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>34% (57/167)</p></td><td style="vertical-align:top"><p>43% (71/167)</p></td><td style="vertical-align:top"><p>44% (73/167)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Imatinib-Resistant Patients</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>33% (41/124)</p></td><td style="vertical-align:top"><p>40% (50/124)</p></td><td style="vertical-align:top"><p>41% (51/124)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Imatinib-Intolerant Patients</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>37% (16/43)</p></td><td style="vertical-align:top"><p>49% (21/43)</p></td><td style="vertical-align:top"><p>51% (22/43)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>a&nbsp;&nbsp; Results reported in recommended starting dose of 100 mg once daily.</p><p>b<strong>&nbsp;&nbsp; </strong>Major molecular response criteria: Defined as BCR-ABL/control transcripts &pound;0.1% by RQ-PCR in peripheral blood samples.</p><p>Based on data 7 years after the last patient was enrolled in the trial, 44% were known to be alive, 31% were known to have died, and 25% had an unknown survival status.</p><p>By 7 years, transformation to either accelerated or blast phase occurred in nine patients on treatment in the 100 mg once-daily treatment group.</p><p>Advanced Phase CML and Ph+ ALL</p><p><em>Dose-Optimization Trial: </em>One randomized open-label trial was conducted in patients with advanced phase CML (accelerated phase CML, myeloid blast phase CML, or lymphoid blast phase CML) to evaluate the efficacy and safety of SPRYCEL administered once daily compared with SPRYCEL administered twice daily. The primary efficacy endpoint was MaHR. A total of 611 patients were randomized to either the SPRYCEL 140&nbsp;mg once-daily or 70 mg twice-daily group. Median duration of treatment was approximately 6 months for both treatment groups. The once-daily schedule demonstrated comparable efficacy (non-inferiority) to the twice-daily schedule on the primary efficacy endpoint; however, the 140 mg once-daily regimen demonstrated improved safety and tolerability.</p><p>Response rates for patients in the 140 mg once-daily group are presented in Table 19.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="5" style="vertical-align:top"><p>Table 19:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy of SPRYCEL in Imatinib-Resistant or -Intolerant Advanced Phase CML and Ph+&nbsp;ALL (2-Year Results)</p></td></tr></tbody><thead><tr><td><p>&nbsp;</p></td><td colspan="4" style="vertical-align:bottom"><p>140 mg Once Daily</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Accelerated<br />(n=158)</p></td><td style="vertical-align:bottom"><p>Myeloid Blast<br />(n=75)</p></td><td style="vertical-align:bottom"><p>Lymphoid Blast<br />(n=33)</p></td><td style="vertical-align:bottom"><p>Ph+&nbsp;ALL<br />(n=40)</p></td></tr></thead><tbody><tr><td><p><strong>MaHR</strong><!--[if supportFields]><span
  style='mso-bookmark:Table_MISC4_2'><span style='mso-bookmark:_msoanchor_1'><span
  style='mso-bookmark:_Toc147808627'></span></span></span><span
  style='mso-element:field-begin'></span><span style='mso-bookmark:Table_MISC4_2'><span
  style='mso-bookmark:_msoanchor_1'><span style='mso-bookmark:_Toc147808627'><span
  class=BMSTableNote><span style='font-size:14.0pt;mso-bidi-font-size:10.0pt'>
  SEQ Table_MISC4 \* alphabetic \* MERGEFORMAT <span style='mso-element:field-separator'></span></span></span></span></span></span><![endif]-->a<!--[if supportFields]><span
  style='mso-bookmark:Table_MISC4_2'><span style='mso-bookmark:_msoanchor_1'><span
  style='mso-bookmark:_Toc147808627'></span></span></span><span
  style='mso-element:field-end'></span><![endif]--><br />&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td><p>66%<br />(59&ndash;74)</p></td><td><p>28%<br />(18&ndash;40)</p></td><td><p>42%<br />(26&ndash;61)</p></td><td><p>38%<br />(23&ndash;54)</p></td></tr><tr><td><p>CHR<!--[if supportFields]><span
  style='mso-bookmark:_msoanchor_1'><span style='mso-bookmark:_Toc147808627'></span></span><span
  style='mso-element:field-begin'></span><span style='mso-bookmark:_msoanchor_1'><span
  style='mso-bookmark:_Toc147808627'><span class=BMSTableNote><span lang=PT-BR
  style='font-size:14.0pt;mso-bidi-font-size:10.0pt;mso-ansi-language:PT-BR;
  mso-no-proof:yes'> SEQ Table_MISC4 Table_MISC4_2 \* alphabetic \* MERGEFORMAT
  <span style='mso-element:field-separator'></span></span></span></span></span><![endif]-->a<!--[if supportFields]><span
  style='mso-bookmark:_msoanchor_1'><span style='mso-bookmark:_Toc147808627'></span></span><span
  style='mso-element:field-end'></span><![endif]--><br />&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td><p>47%<br />(40&ndash;56)</p></td><td><p>17%<br />(10&ndash;28)</p></td><td><p>21%<br />(9&ndash;39)</p></td><td><p>33%<br />(19&ndash;49)</p></td></tr><tr><td><p>NEL<!--[if supportFields]><span style='mso-bookmark:
  _msoanchor_1'><span style='mso-bookmark:_Toc147808627'></span></span><span
  style='mso-element:field-begin'></span><span style='mso-bookmark:_msoanchor_1'><span
  style='mso-bookmark:_Toc147808627'> SEQ Table_MISC4 Table_MISC4_2 \*
  alphabetic \* MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]-->a<!--[if supportFields]><span
  style='mso-bookmark:_msoanchor_1'><span style='mso-bookmark:_Toc147808627'></span></span><span
  style='mso-element:field-end'></span><![endif]--><br />&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td><p>19%<br />(13&ndash;26)</p></td><td><p>11%<br />(5&ndash;20)</p></td><td><p>21%<br />(9&ndash;39)</p></td><td><p>5%<br />(1&ndash;17)</p></td></tr><tr><td><p><strong>MCyR</strong><!--[if supportFields]><span
  style='mso-bookmark:Table_MISC4_3'><span style='mso-bookmark:_Toc147808627'><span
  style='mso-bookmark:_msoanchor_1'></span></span></span><span
  style='mso-element:field-begin'></span><span style='mso-bookmark:Table_MISC4_3'><span
  style='mso-bookmark:_Toc147808627'><span style='mso-bookmark:_msoanchor_1'><span
  class=BMSTableNote><span style='font-size:14.0pt;mso-bidi-font-size:10.0pt'>
  SEQ Table_MISC4 \* alphabetic \* MERGEFORMAT <span style='mso-element:field-separator'></span></span></span></span></span></span><![endif]-->b<!--[if supportFields]><span
  style='mso-bookmark:Table_MISC4_3'><span style='mso-bookmark:_Toc147808627'><span
  style='mso-bookmark:_msoanchor_1'></span></span></span><span
  style='mso-element:field-end'></span><![endif]--><br />&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td><p>39%<br />(31&ndash;47)</p></td><td><p>28%<br />(18&ndash;40)</p></td><td><p>52%<br />(34&ndash;69)</p></td><td><p>70%<br />(54&ndash;83)</p></td></tr><tr><td><p>CCyR<br />&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td><p>32%<br />(25&ndash;40)</p></td><td><p>17%<br />(10&ndash;28)</p></td><td><p>39%<br />(23&ndash;58)</p></td><td><p>50%<br />(34&ndash;66)</p></td></tr></tbody></table><p><!--[if supportFields]><span
style='mso-bookmark:_Toc147808627'><span style='mso-bookmark:_msoanchor_1'></span></span><span
style='mso-element:field-begin'></span><span style='mso-bookmark:_Toc147808627'><span
style='mso-bookmark:_msoanchor_1'><span style='color:windowtext'><span
style='mso-spacerun:yes'> </span>SEQ Table_MISC4 Table_MISC4_2 \* alphabetic \*
MERGEFORMAT </span><span style='mso-element:field-separator'></span></span></span><![endif]-->a<!--[if supportFields]><span
style='mso-bookmark:_Toc147808627'><span style='mso-bookmark:_msoanchor_1'></span></span><span
style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp; Hematologic response criteria (all responses confirmed after 4 weeks): Major hematologic response: (MaHR) = complete hematologic response (CHR)&nbsp;+&nbsp;no evidence of leukemia (NEL).</p><p>CHR: WBC &pound; institutional ULN, ANC &sup3;1000/mm3, platelets &ge;100,000/mm3, no blasts or promyelocytes in peripheral blood, bone marrow blasts &pound;5%, &lt;5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt;20%, and no extramedullary involvement.</p><p>NEL: same criteria as for CHR but ANC &sup3;500/mm3 and &lt;1000/mm3, or platelets &sup3;20,000/mm3 and &pound;100,000/mm3.</p><p><!--[if supportFields]><span
style='mso-bookmark:_Toc147808627'><span style='mso-bookmark:_msoanchor_1'></span></span><span
style='mso-element:field-begin'></span><span style='mso-bookmark:_Toc147808627'><span
style='mso-bookmark:_msoanchor_1'><span style='color:windowtext'><span
style='mso-spacerun:yes'> </span>SEQ Table_MISC4 Table_MISC4_3 \* alphabetic \*
MERGEFORMAT </span><span style='mso-element:field-separator'></span></span></span><![endif]-->b<!--[if supportFields]><span
style='mso-bookmark:_Toc147808627'><span style='mso-bookmark:_msoanchor_1'></span></span><span
style='mso-element:field-end'></span><![endif]-->&nbsp;&nbsp; MCyR combines both complete (0% Ph+ metaphases) and partial (&gt;0%&ndash;35%) responses.</p><p>CI =&nbsp;confidence interval. ULN =&nbsp;upper limit of normal range.</p><p>&nbsp;</p><p>In the SPRYCEL 140 mg once-daily group, the median time to MaHR was 1.9 months (min-max: 0.7-14.5) for patients with accelerated phase CML, 1.9 months (min-max: 0.9-6.2) for patients with myeloid blast phase CML, and 1.8 months (min-max: 0.9-2.8) for patients with lymphoid blast phase CML.</p><p>In patients with myeloid blast phase CML, the median duration of MaHR was 8.1 months (min-max:2.7-21.1) and 9.0 (min-max:1.8-23.1) months for the 140 mg once-daily group and the 70 mg twice-daily group, respectively. In patients with lymphoid blast phase CML, the median duration of MaHR was 4.7 months (min-max: 3.0-9.0) and 7.9 months (min-max: 1.6-22.1) for the 140 mg once-daily group and the 70 mg twice-daily group, respectively. In patients with Ph+ ALL who were treated with SPRYCEL 140 mg once daily, the median duration of MaHR was 4.6 months (min-max: 1.4-10.2). The medians of progression-free survival for patients with Ph+ ALL treated with SPRYCEL 140 mg once-daily and 70 mg twice-daily were 4.0 months (min-max: 0.4-11.1) and 3.1 months (min-max: 0.3-20.8), respectively.</p><p>CML in Pediatric Patients</p><p>The efficacy of SPRYCEL in pediatric patients was evaluated in two pediatric studies of 97 patients with chronic phase CML. Among 97 patients with chronic phase CML treated in two pediatric studies, an open-label, non-randomized dose-ranging trial and an open-label, non-randomized, single-arm trial, 51 patients (exclusively from the single-arm trial) had newly diagnosed chronic phase CML and 46 patients (17 from the dose-ranging trial and 29 from the single-arm trial) were resistant or intolerant to previous treatment with imatinib. Ninety-one of the 97 pediatric patients were treated with SPRYCEL tablets 60 mg/m<sup>2</sup> once daily (maximum dose of 100 mg once daily for patients with high BSA). Patients were treated until disease progression or unacceptable toxicity.</p><p>Baseline demographic characteristics of the 46 imatinib resistant or intolerant patients were: median age 13.5 years (range 2 to 20 years), 78.3% White, 15.2% Asian, 4.4% Black, 2.2% other, and 52% female. Baseline characteristics of the 51 newly diagnosed patients were: median age 12.8 years (range 1.9 to 17.8 years), 60.8% White, 31.4% Asian, 5.9% Black, 2% Other, and 49% female.</p><p>Median duration of follow-up was 5.2 years (range 0.5 to 9.3 years) for the imatinib resistant or intolerant patients and 4.5 years (range 1.3 to 6.4 years) for the newly diagnosed patients, respectively. Efficacy results for the two pediatric studies are summarized in Table 20.</p><p>Table 20 shows increasing trend for response for CCyR, MCyR, and MMR across time (3 months to 24 months). The increasing trend in response for all three endpoints is seen in both the newly diagnosed and imatinib resistant or intolerant patients.</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="5"><p>Table 20:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy of SPRYCEL in Pediatric Patients with CP-CML<br />Cumulative Response Over Time by Minimum Follow-Up Period</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>3 months</p></td><td><p>6 months</p></td><td><p>12 months</p></td><td><p>24 months</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>CCyR </strong></p><p><strong>(95% CI)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Newly diagnosed</p><p>(N = 51)a<br />&nbsp;</p></td><td style="vertical-align:top"><p>43.1%</p><p>(29.3, 57.8)</p></td><td style="vertical-align:top"><p>66.7%</p><p>(52.1, 79.2)</p></td><td style="vertical-align:top"><p>96.1%</p><p>(86.5, 99.5)</p></td><td style="vertical-align:top"><p>96.1%</p><p>(86.5, 99.5)</p></td></tr><tr><td style="vertical-align:top"><p>Prior imatinib</p><p>(N = 46)b</p></td><td style="vertical-align:top"><p>45.7%<br />(30.9, 61.0)</p></td><td style="vertical-align:top"><p>71.7%<br />(56.5, 84.0)</p></td><td style="vertical-align:top"><p>78.3%<br />(63.6, 89.1)</p></td><td style="vertical-align:top"><p>82.6%<br />(68.6, 92.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MCyR </strong></p><p><strong>(95% CI)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Newly diagnosed</p><p>(N = 51)a</p></td><td style="vertical-align:top"><p>60.8%</p><p>(46.1, 74.2)</p></td><td style="vertical-align:top"><p>90.2%</p><p>(78.6, 96.7)</p></td><td style="vertical-align:top"><p>98.0%</p><p>(89.6, 100)</p></td><td style="vertical-align:top"><p>98.0%</p><p>(89.6, 100)</p></td></tr><tr><td style="vertical-align:top"><p>Prior imatinib</p><p>(N = 46)b</p></td><td style="vertical-align:top"><p>60.9%<br />(45.4, 74.9)</p></td><td style="vertical-align:top"><p>82.6%<br />(68.6, 92.2)</p></td><td style="vertical-align:top"><p>89.1%<br />(76.4, 96.4)</p></td><td style="vertical-align:top"><p>89.1%<br />(76.4, 96.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MMR </strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Newly diagnosed</p><p>(N = 51)a</p></td><td style="vertical-align:top"><p>7.8%</p><p>(2.2, 18.9)</p></td><td style="vertical-align:top"><p>31.4%&nbsp;</p><p>(19.1, 45.9)</p></td><td style="vertical-align:top"><p>56.9%&nbsp;</p><p>(42.2, 70.7)</p></td><td style="vertical-align:top"><p>74.5%&nbsp;</p><p>(60.4, 85.7)</p></td></tr><tr><td style="vertical-align:top"><p>Prior imatinib</p><p>(N = 46)b</p></td><td style="vertical-align:top"><p>15.2%</p><p>(6.3, 28.9)</p></td><td style="vertical-align:top"><p>26.1%</p><p>(14.3, 41.1)</p></td><td style="vertical-align:top"><p>39.1%</p><p>(25.1, 54.6)</p></td><td style="vertical-align:top"><p>52.2%</p><p>(36.9, 67.1)</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp; Patients from pediatric study of newly diagnosed CP-CML receiving oral tablet formulation.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients from pediatric studies of imatinib-resistant or -intolerant CP-CML receiving oral tablet formulation.</p><p>&nbsp;</p><p>With a median follow-up of 4.5 years in newly diagnosed patients, the median durations of CCyR, MCyR, MMR could not be estimated as more than half of the responding patients had not progressed at the time of data cut-off. Range of duration of response was (2.5+ to 66.5+ months for CCyR), (1.4 to 66.5+ months for MCyR),&nbsp;and (5.4+ to 72.5+ months for subjects who achieved MMR by month 24 and 0.03+ to 72.5+ months for subjects who achieved MMR at any time), where &lsquo;+&rsquo; indicates a censored observation.</p><p>With a median follow-up of 5.2 years in imatinib-resistant or -intolerant patients, the median durations of CCyR, MCyR, and MMR could not be estimated as more than half the responding patients had not progressed at the time of data cut-off. Range of duration of response was (2.4 to 86.9+ months for CCyR), (2.4 to 86.9+ months for MCyR),&nbsp;and (2.6+ to 73.6+ months for MMR), where &lsquo;+&rsquo; indicates a censored observation.</p><p>The median time to response for MCyR was 2.9 months (95% CI: 2.8 months, 3.5 months) in the pooled imatinib-resistant/intolerant CP-CML patients. The median time to response for CCyR was 3.3 months (95% CI: 2.8 months, 4.7 months) in the pooled imatinib-resistant/intolerant CP-CML patients. The median time to response for MMR was 8.3 months (95% CI: 5.0 months, 11.8 months) in the pooled imatinib-resistant/intolerant CP-CML patients.</p><p>The median time to response for MCyR was 3.0 months (95% CI: 2.8 months, 4.3 months) in the newly diagnosed treatment-na&iuml;ve CP-CML patients. The median time to response for CCyR was 5.5 months (95% CI: 3.0 months, 5.7 months) in the newly diagnosed treatment-na&iuml;ve CP-CML patients. The median time to response for MMR was 8.9 months (95% CI: 6.2 months, 11.7 months) in the newly diagnosed treatment-na&iuml;ve CP-CML patients.</p><p>In the Phase II pediatric study, 1 newly diagnosed patient and 2 imatinib-resistant or -intolerant patients progressed to blast phase CML.</p><p>Ph+ ALL in Pediatric Patients</p><p>The efficacy of SPRYCEL in combination with chemotherapy was evaluated in a single cohort (cohort 1) of Study CA180372, a multicenter, multiple-cohort study of pediatric patients with newly diagnosed B-cell precursor Ph+ ALL. The 78 patients in cohort 1 received SPRYCEL at a daily dose of 60 mg/m2 for up to 24 months, in combination with chemotherapy. The backbone chemotherapy regimen was the AIEOP-BFM ALL 2000 multi-agent chemotherapy protocol.</p><p>Patients had a median age of 10.4 years (range 2.6 to 17.9 years) and included 20 patients (25%) 2 to 6 years of age, 37 patients (46%) 7 to 12 years of age, and 24 patients (30%) 13 to 17 years of age. Eighty-two percent of patients were white, and 55% were male. Thirty-two patients (41%) had a white blood cell count (WBC) of &ge;50,000 mcl at diagnosis, and 17 patients (22%) had extramedullary disease.</p><p>Efficacy was established on the basis of 3-year event-free survival (EFS), defined as the time from the start of SPRYCEL to lack of complete response at the end of the third high risk block, relapse, secondary malignancy, or death from any cause. The 3-year EFS binary rate for patients on Study CA180372 was 64.1% (95% CI: 52.4, 74.7). At the end of induction, 75 patients (96%) had a bone marrow with &lt;5% lymphoblasts, and 76 patients (97%) achieved this by the end of consolidation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of dasatinib exhibits dose proportional increases in AUC and linear elimination characteristics over the dose range of 15 mg/day (0.15 times the lowest approved recommended dose) to 240 mg/day (1.7 times the highest approved recommended dose).</p><p>At 100 mg QD, the maximum concentration at steady state (C<sub>max</sub>) is 82.2 ng/mL (CV% 69%), area under the plasma drug concentration time curve (AUC) is 397 ng/mL*hr (CV% 55%). The clearance of dasatinib is found to be time-invariant. When administered to adult healthy subjects as dispersed tablets in juice, the adjusted geometric mean ratio was 0.97 (90% CI: 0.85, 1.10) for C<sub>max</sub> and 0.84 (90% CI: 0.78, 0.91) for AUC as compared to intact tablets.</p><p>Absorption</p><p>The maximum plasma concentrations (C<sub>max</sub>) of dasatinib are observed between 0.5 hours and 6 hours (T<sub>max</sub>) following oral administration.</p><p>Food Effect</p><p>A high-fat meal increased the mean AUC of dasatinib following a single dose of 100 mg by 14%. The total calorie content of the high-fat meal was 985 kcal. The calories derived from fat, carbohydrates, and protein were 52%, 34%, and 14% for the high-fat meal.</p><p>Distribution</p><p>The apparent volume of distribution is 2505 L (CV% 93%).</p><p>Binding of dasatinib to human plasma proteins <em>in vitro</em> was approximately 96% and of its active metabolite was 93%, with no concentration dependence over the range of 100 ng/mL to 500 ng/mL.</p><p>Dasatinib is a P-gp substrate <em>in vitro</em>.</p><p>Elimination</p><p>The mean terminal half-life of dasatinib is 3 hours to 5 hours. The mean apparent oral clearance is 363.8 L/hr (CV% 81.3%).</p><p>Metabolism</p><p>Dasatinib is metabolized in humans, primarily by CYP3A4. CYP3A4 is the primary enzyme responsible for the formation of the active metabolite. Flavin-containing monooxygenase 3 (FMO-3) and uridine diphosphate-glucuronosyltransferase (UGT) enzymes are also involved in the formation of dasatinib metabolites.</p><p>The exposure of the active metabolite, which is equipotent to dasatinib, represents approximately 5% of the AUC of dasatinib. The active metabolite of dasatinib is unlikely to play a major role in the observed pharmacology of the drug. Dasatinib also has several other inactive oxidative metabolites.</p><p>Excretion</p><p>Elimination is primarily via the feces. Following a single radiolabeled dose of oral dasatinib, 4% of the administered radioactivity was recovered in the urine and 85% in the feces within 10 days. Unchanged dasatinib accounted for 0.1% of the administered dose in the urine and 19% of the administered dose in the feces with the remainder of the dose being metabolites.</p><p>Specific Populations</p><p>Age (15 to 86 years old), sex, and renal impairment (creatinine clearance 21.6 mL/min to 342.3 mL/min as estimated by Cockcroft Gault) have no clinically relevant effect on the pharmacokinetics of dasatinib.</p><p>Pediatric Patients</p><p>The pharmacokinetics of dasatinib were evaluated in 43 pediatric patients with leukemia or solid tumors at oral doses ranging from 60 mg/m<sup>2</sup> to 120 mg/m<sup>2</sup> once daily, taken with or without food. The pharmacokinetics showed dose proportionality with a dose-related increase in exposure. The mean T<sub>max</sub> was observed between 0.5 hours and 6 hours and the mean half-life was 2 hours to 5 hours. The geometric mean (CV%) of body weight normalized clearance in these 43 pediatric patients is 5.98 (41.5%) L/h/kg. In pediatric patients with a dosing regimen of 60&nbsp;mg/m<sup>2</sup>, the model simulated geometric mean (CV%) steady-state plasma average concentrations of dasatinib were 14.7 (64.6%) ng/mL (for 2 to &lt;6 years old), 16.3 (97.5%) ng/mL (for 6 to &lt;12 years old), and 18.2 (67.7%) ng/mL (for 12 years and older) <em>[see Posology and method of administration (4.2)]</em>. Dasatinib clearance and volume of distribution change with body weight in pediatric patients. Dasatinib has not been studied in patients &lt;1 year old.</p><p>The bioavailability of dispersed tablets in pediatric patients was estimated to be 36% lower than that of intact tablets.</p><p>Patients with Hepatic Impairment</p><p>Compared to subjects with normal liver function, patients with moderate hepatic impairment (Child Pugh B) had decreases in mean Cmax by 47% and mean AUC by 8%. Patients with severe hepatic impairment (Child Pugh C) had decreases in mean Cmax by 43% and in mean AUC by 28% compared to the subjects with normal liver function.</p><p>Drug Interaction Studies</p><p>Cytochrome P450 Enzymes</p><p>The coadministration of ketoconazole (strong CYP3A4 inhibitor) twice daily increased the mean Cmax of dasatinib by 4-fold and the mean AUC of dasatinib by 5-fold following a single oral dose of 20 mg.</p><p>The coadministration of rifampin (strong CYP3A4 inducer) once daily decreased the mean C<sub>max</sub> of dasatinib by 81% and the mean AUC of dasatinib by 82%.</p><p>Dasatinib is a time-dependent inhibitor of CYP3A4. Dasatinib does not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 2E1. Dasatinib does not induce CYP enzymes.</p><p>Gastric Acid Reducing Agents</p><p>The administration of 30 mL of aluminum hydroxide/magnesium hydroxide 2 hours prior to a single dose of SPRYCEL was associated with no relevant change in the mean AUC of dasatinib; however, the mean C<sub>max</sub> of dasatinib was increased by 26%.</p><p>The simultaneous administration of 30 mL of aluminum hydroxide/magnesium hydroxide with a single dose of SPRYCEL was associated with a 55% reduction in the mean AUC of dasatinib and a 58% reduction in the mean C<sub>max</sub> of dasatinib.</p><p>The administration of a single dose of SPRYCEL 10 hours following famotidine (H<sub>2</sub> antagonist) reduced the mean AUC of dasatinib by 61% and the mean C<sub>max</sub> of dasatinib by 63%.</p><p>The administration of a single 100 mg dose of SPRYCEL 22 hours following a 40 mg dose of omeprazole (proton pump inhibitor) at steady state reduced the mean AUC of dasatinib by 43% and the mean C<sub>max</sub> of dasatinib by 42%.</p><p>Transporters</p><p>Dasatinib is not an inhibitor of P-gp <em>in vitro</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p>In a 2-year carcinogenicity study, rats were administered oral doses of dasatinib at 0.3, 1, and 3 mg/kg/day. The highest dose resulted in a plasma drug exposure (AUC) level approximately 60% of the human exposure at 100 mg once daily. Dasatinib induced a statistically significant increase in the combined incidence of squamous cell carcinomas and papillomas in the uterus and cervix of high-dose females and prostate adenoma in low-dose males.</p><p>Dasatinib was clastogenic when tested <em>in vitro</em> in Chinese hamster ovary cells, with and without metabolic activation. Dasatinib was not mutagenic when tested in an <em>in vitro</em> bacterial cell assay (Ames test) and was not genotoxic in an <em>in vivo</em> rat micronucleus study.</p><p>Dasatinib did not affect mating or fertility in male and female rats at plasma drug exposure (AUC) similar to the human exposure at 100&nbsp;mg daily. In repeat dose studies, administration of dasatinib resulted in reduced size and secretion of seminal vesicles, and immature prostate, seminal vesicle, and testis. The administration of dasatinib resulted in uterine inflammation and mineralization in monkeys, and cystic ovaries and ovarian hypertrophy in rodents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core </u></p><p>Lactose monohydrate</p><p>Microcrystalline cellulose</p><p>Croscarmellose sodium</p><p>Hydroxypropyl cellulose</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Film-coating</u></p><p>Hypromellose</p><p>Titanium dioxide (E171)</p><p>Macrogol 400</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Storage</p><p style="text-align:left">Do not store SPRYCEL tablets above 30&deg;C.<sup> </sup></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:80%"><thead><tr><td><p><strong>Strength</strong></p></td><td><p><strong>Description</strong></p></td><td><p><strong>Tablets per Bottle</strong></p></td></tr></thead><tbody><tr><td><p>20 mg</p></td><td><p>white to off-white, biconvex, round, film‑coated tablet with &ldquo;BMS&rdquo; debossed on one side and &ldquo;527&rdquo; on the other side</p></td><td><p>60</p></td></tr><tr><td><p>50 mg</p></td><td><p>white to off-white, biconvex, oval, film‑coated tablet with &ldquo;BMS&rdquo; debossed on one side and &ldquo;528&rdquo; on the other side</p></td><td><p>60</p></td></tr><tr><td><p>70 mg</p></td><td><p>white to off-white, biconvex, round, film‑coated tablet with &ldquo;BMS&rdquo; debossed on one side and &ldquo;524&rdquo; on the other side</p></td><td><p>60</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SPRYCEL tablets consist of a core tablet, surrounded by a film coating to prevent exposure of healthcare professionals to the active substance. The use of latex or nitrile gloves for appropriate disposal when handling tablets that are inadvertently crushed or broken is recommended, to minimize the risk of dermal exposure.</p><p>Handling</p><p>SPRYCEL is an antineoplastic drug that is considered a hazardous medication.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In healthcare settings, use designated area for medication storage and restrict access to only authorized personnel.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To minimize the risk of dermal exposure, always wear chemotherapy gloves and sleeve covers when handling SPRYCEL. This includes all handling activities in clinical settings, pharmacies, storerooms and home healthcare settings, including receiving, unpacking, and storing within a facility.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For transportation of intact tablet within the facility, wear single chemotherapy gloves and place in double bag or in a sealed container.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets should not be divided, broken or crushed. This might produce powder that can contaminate workplace surfaces.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution should be observed in handling broken or crushed tablets; wear double chemotherapy gloves and place in double bag or in a sealed container. Avoid direct contact with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When manipulations such as compounding, crushing, cutting, or splitting are necessary, these should be performed within a ventilated engineering enclosure and/or augment the control of generated aerosols using supplementary controls such as glove bags or pill pouches that contain the hazardous drug during and after the crushing process.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wear double chemotherapy gloves, protective gown and sleeve covers. Add eye/face protection and respiratory protection [N95] if compounding is done outside of the ventilated engineering control. Hair and shoe covers should be worn.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When clinically appropriate, add liquid or moist food products to crushed hazardous drug product as soon as possible after crushing, to avoid the potential of subsequent aerosol dissemination.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For medication administration, wear single chemotherapy gloves with intact and coated tablets and double chemotherapy gloves with cut or crushed tablets. Add eye and face protection if there is the potential to contact vomit or if patient may resist or is pre-disposed to spitting out.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; People who are pregnant should avoid exposure to crushed or broken coated tablets.</p><p>Disposal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wear double chemotherapy gloves and protective gown for any disposal or cleaning activity of medication contaminated waste.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid creating dusts. Place in sealed bags for disposal. Use caution when closing bags as pushing waste down may force hazardous drug dusts up into the user&rsquo;s face.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For disposal of drugs and metabolites in body fluids, wear chemotherapy gloves and protective gown. Fold soft materials (sheets, hygiene care products) inward to prevent leakage and place in sealed bags.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In case of spill, limit access to area, use wet wiping method (absorbent pads for liquid spills). Place in sealed bags for disposal. Disinfection, deactivation or decontamination agents may be necessary.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>Patient Counseling Information</p><p>Advise the patient to read the Patient Information Leaflet.</p><p>Myelosuppression</p><p>Inform patients of the possibility of developing low blood cell counts. Advise patients to immediately report fever, particularly in association with any suggestion of infection <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Bleeding</p><p>Inform patients of the possibility of serious bleeding and to report immediately any signs or symptoms suggestive of hemorrhage (unusual bleeding or easy bruising) <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>Fluid Retention</p><p>Patients should be informed of the possibility of developing fluid retention (swelling, weight gain, dry cough, chest pain on respiration, or shortness of breath) and advised to seek medical attention promptly if those symptoms arise <em>[see Special warnings and precautions for use (4.4)].</em></p><p>Cardiovascular Toxicity</p><p>Inform patients of the possibility of developing cardiovascular toxicity, including cardiac ischemic events, cardiac-related fluid retention, conduction abnormalities, and TIAs. Advise patients to seek immediate medical attention if symptoms suggestive of cardiovascular toxicity occur, such as chest pain, shortness of breath, palpitations, transient vision problems, or slurred speech <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>Pulmonary Arterial Hypertension</p><p>Inform patients of the possibility of developing pulmonary arterial hypertension (dyspnea, fatigue, hypoxia, and fluid retention) and advise them to seek medical attention promptly if those symptoms arise <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>Tumor Lysis Syndrome</p><p>Inform patients to immediately report and seek medical attention for any symptoms such as nausea, vomiting, weakness, edema, shortness of breath, muscle cramps, and seizures, which may indicate tumor lysis syndrome <em>[see Special warnings and precautions for use (4.4)]. </em></p><p>Growth and Development in Pediatric Patients</p><p>Inform pediatric patients and their caregivers of the possibility of developing bone growth abnormalities, bone pain, or gynecomastia and advise them to seek medical attention promptly if those symptoms arise <em>[see Special warnings and precautions for use (4.4)]</em>.</p><p>Embryo-Fetal Toxicity</p><p>Advise pregnant women of the potential risk to a fetus <em>[see Special warnings and precautions for use (4.4) and Fertility, pregnancy and lactation (4.6)].</em></p><p>Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with SPRYCEL and for 30 days after the last dose. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking SPRYCEL <em>[see Special warnings and precautions for use (4.4) and Fertility, pregnancy and lactation (4.6)]</em>.</p><p>Lactation</p><p>Advise women that breastfeeding is not recommended during treatment with SPRYCEL and for 2 weeks after the final dose <em>[see </em><em>Fertility, pregnancy and lactation (4.6)]</em>.</p><p>Gastrointestinal Complaints</p><p>Inform patients that they may experience nausea, vomiting, or diarrhea with SPRYCEL. Advise patients to seek medical attention if these symptoms are bothersome or persistent.</p><p>Advise patients using antacids to avoid taking SPRYCEL and antacids less than 2 hours apart <em>[see Interaction with other medicinal products and other forms of interaction (4.5)]</em>.</p><p>Pain</p><p>Inform patients that they may experience headache or musculoskeletal pain with SPRYCEL. Advise patients to seek medical attention if these symptoms are bothersome or persistent.</p><p>Fatigue</p><p>Inform patients that they may experience fatigue with SPRYCEL. Advise patients to seek medical attention if this symptom is bothersome or persistent.</p><p>Rash</p><p>Inform patients that they may experience skin rash with SPRYCEL. Advise patients to seek medical attention if this symptom is bothersome or persistent.</p><p>Lactose</p><p>Inform patients that SPRYCEL contains 135 mg of lactose monohydrate in a 100‑mg daily dose and 189&nbsp;mg of lactose monohydrate in a 140-mg daily dose.</p><p><em>Hepatotoxicity</em></p><p>Advise patients that SPRYCEL can cause hepatotoxicity and that patients with previous history of liver diseases may be at risk. Advise patients to seek immediate medical attention if any symptoms suggestive of hepatotoxicity occur, such as abdominal pain, jaundice and scleral icterus, anorexia, bleeding, bruising, and dark-colored urine <em>[see Special Warnings and Precautions for use (4.4)]</em>.</p><p>&nbsp;</p><p>Instructions for Taking SPRYCEL</p><p>Missed Dose</p><p>Advise patients that if they miss a dose of SPRYCEL, they should take the next scheduled dose at its regular time. The patient should not take two doses at the same time.</p><p>Grapefruit Juice</p><p>Advise patients not to drink grapefruit juice as it may increase the amount of SPRYCEL in their blood and therefore increase their risk of adverse reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Bristol-Myers Squibb Company
Princeton, New Jersey 08543 
USA

Manufactured by:
AstraZeneca Pharmaceuticals LP 4601 Highway 62 East
Mount Vernon, Indiana 47620 USA

Patheon Inc
2100 Syntex Court, Mississauga
Ontario L5N 7K9
Canada


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>